WO2001091853A1 - Electrokinetic delivery device - Google Patents
Electrokinetic delivery device Download PDFInfo
- Publication number
- WO2001091853A1 WO2001091853A1 PCT/US2001/016069 US0116069W WO0191853A1 WO 2001091853 A1 WO2001091853 A1 WO 2001091853A1 US 0116069 W US0116069 W US 0116069W WO 0191853 A1 WO0191853 A1 WO 0191853A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- electrode
- applicator
- substance
- medicament
- treatment site
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
- A61N1/0432—Anode and cathode
- A61N1/0436—Material of the electrode
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
- A61N1/0432—Anode and cathode
- A61N1/044—Shape of the electrode
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
- A61N1/0448—Drug reservoir
Definitions
- the present invention relates generally to the electrokinetic mass transfer of substances into and/or extracting substances from tissue and particularly to apparatus and methods for extracting, containing and/or delivering substance, e.g., a medicament to a treatment site.
- Electrokinetic delivery of medicaments for applying medication locally through an individual's skin is known.
- One type of electrokinetic delivery mechanism is iontophoresis, i.e., the application of an electric field to the skin to enhance the skin's permeability and to deliver various ionic agents, e.g., ions of soluble salts or other drugs.
- iontophoretic transdermal or transmucocutaneous delivery techniques have obviated the need for hypodermic injection for many medicaments, thereby eliminating the concomitant problem of trauma, pain and risk of infection to the individual.
- electrokinetic delivery mechanisms include electroosmosis, electroporation, electromigration, electrophoresis and endosmose, any or all of which are generally known as electrotransport, electromolecular transport or iontophoretic methods.
- the electrokinetic delivery mechanism may also be accompanied by ultrasonic vibration to further facilitate electrokinetic transport of the substance, e.g., by opening pores in the skin.
- Ultrasound may be employed in a number of ways such as (i) traditional piezoelectric elements, (ii) Application Specific Integrated Circuits (ASIC) with ultrasound transmitter built in or (iii) by thin foil sheets with incorporated piezoelectric dipole elements.
- ASIC Application Specific Integrated Circuits
- a portable, self-contained, hand-held lightweight, compact and wireless electrokinetic device for delivering or removing a substance, e.g., a medicament, and a unit dosage substance applicator for use with the device for the self-administration of a medicament to the skin.
- substance is meant a medicament as well as natural or homeopathic products that may be outside the definition of medicament, e.g., inks and pigments for tattoos, and more generally includes any substance capable of electrokinetic transport through skin or mucocutaneous membrane, e.g., into a treatment site or from a site, e.g., for diagnostic purposes.
- medicament any chemical or biologic that may be used on or administered to humans or animals as an aid in the diagnosis, treatment or prevention of disease or other abnormal or cosmetic condition or for the relief of pain or to control, diagnose or improve any physiologic or pathologic condition.
- Major therapeutic classes include but are not limited to, ACE inhibitors, such as ranitidine, anti-infectives such as antibacterials, antivirals and antimicrobials, vasodilators, including general, coronary, peripheral and cerebral, adrenocortical steroids, alpha-adrenergic agonists, alpha-adrenergic antagonists, selective alpha-two-adrenergic agonists, analgesics, and analgesic combinations, androgens, local and general anesthetics, antiaddictive agents, antiandrogens, antiarrhythmic agents, antiasthmatic agents, anticholinergic agents, anticholinesterase agents, xanthine derivatives, cardiovasculars including calcium channel blockers such as nifedipine, beta agonists such as dobutamine and ritodine, anticoagulants, including heparin, anticonvulsants, antidiabetic agents, antidiarrheal agents, antidiuretic, antiem
- medicaments are interferons, e.g., ⁇ -2b interferon, amphotericin ⁇ , angiopeptin, baclofen, bepridil, buserelin, buspirone, calcitonin, ciclopirox, olamine, copper, cyclosporin, zinc, tropisetron, vapreotide, vasopressin, vasopressin antagonist analogs, verapamil, warfarin, zacopride, zotasetron, cromolyn sodium, diltiazem, felodipine, isradipine, nicardipine, nifedipine, nimodipine, nitredipine, verapamil, isoproterenol, carterolol, labetalol, levobunolol, minoxidil, nadolol, penbuterol, pin
- benzodiazepines such as alprazolam, brotizolam, chlordiazepoxide, clobazam, clonazepam, clorazepate, demoxepam, diazepam, flumazenil, flurazepam, halazepam, lorazepam, midazolam, nitrazepam, nordazepam, oxazepam, prazepam, quazepam, temazepam, triazolam and the like; antimuscarinic medicaments such as anistropine, atropine, clininium, cyclopentolate, dicyclomine, flavoxate, glycopyrrolate, hexocyclium, homatropine, ipratropium, isopropamide, mepenzolate, methantheline, oxyphencyclimine, pirenzepine, propantheline,
- medicaments such as anti-virals, for treating human papilloma virus, (HPV), e.g., warts (common, flat, plantar and genital), examples of which are Imiquimod® sold as AldaraTM by 3M for genital warts, a type (HPV), Acyclovir®, sodium salicylate, tretinion, benzoyl peroxide, bleomycin, interferons, Podocon-25, OTC products such as Wart Off by Pfizer and Compound W by MedTech or anti-picomavirus class substances, e.g., Pleconaril, to treat coughs and colds, anti-inflammatory medicaments such as dexamethasone and anti-bacterial agents, proteins, as well as steroids and salts thereof, non-steroidal anti-inflammatory drugs (NSAIDs), and salts thereof, hormones, cytokines, viruses, bacteria, DNA,
- HPV human papilloma virus
- warts common, flat, plantar
- bleaching agents e.g., Eldopaque 4% by ICN Pharmaceuticals, or a combination of Ketorolac, hydroquinone 4%, Glycolic Acid, lactic acid with suitable vehicle and anesthetics, such as lidocaine, xylocaine, prontocaine, prilocaine, fetanyl, remifentanil, sufentanil, alfentanil, novocaine, procaine, morphine HCL and EMLA either in stand alone fashion or with a vasodilator such as epinephrine.
- bleaching agents e.g., Eldopaque 4% by ICN Pharmaceuticals, or a combination of Ketorolac, hydroquinone 4%, Glycolic Acid, lactic acid with suitable vehicle and anesthetics, such as lidocaine, xylocaine, prontocaine, prilocaine, fetanyl, remifentanil, suf
- medicaments which inhibit fusion between the plasma membrane and viruses and other adventitious agents to prevent entry by viruses and/or other adventitious agents into cells may also be electrokinetically delivered, e.g., behenyl alcohols such as n-disocanol, its analogs or derivatives.
- Hair growth may be stimulated by Propecia (finasteride), minoxidil, blocking antidihydrotestosterones or antidihydroestrogens.
- Hair removal may be accomplished by dyeing the hair and or hair root to facilitate removal by laser means or by electrokinetically using, e.g., dihydrotestostersone or dihydroandrogens or dihydroestrogens.
- tattoos either temporary (reversible) or permanent may be applied to a treatment site and tattoos when permanent may be removed using suitable medicaments and the instant invention.
- Water soluble dyes and decals or templates may be employed in conjunction with the device and applicators.
- Prostate conditions e.g., prostatitis may be treated with antineoplastics.
- NSAIDs such as ketorolac or medicaments such as Benzamycin, benzoyl perixode, cleocin, T-Stat, over the counter (OTC) products two examples of which are Clearasil and Benz
- Psoriasis may be treated with an antimetabolite, retinoids, synthetic vitamin D, i.e., calciprotriene, cyclosporin A (CSA), Aristocort, from Lederle, anthrax-derm, by Dermik, methotrexate, cortisone like compounds psoralen or anthalin.
- Eczema and contact or atopic dermatitis may be treated with corticosteroids or antihistamines.
- Spider veins may be treated with antiangiogenics, or coagulants (clotting factors or fragmented cellulose polymer). Fluoride treatment of exposed single site hypersensitive dentin may be performed with this device and applicator system.
- Canker sores and RAS may be treated with, e.g., benzoin or sodium fluoride.
- Post herpetic neuralgia may be treated with local anesthetics mentioned throughout this disclosure and/or with antivirals, e.g., Acyclovir or combinations of anesthetic and antiviral.
- Erectile dysfunction may also be treated (transcutaneously at site of concern) using prostaglandins such as PGE or alprostadil, nitroglycerin, and the like or papaverine, yohimbine and the like or sildenafil citrate, i.e., iOS, or apomorphine HCl.
- diagnostic uses i.e., removal or extraction of animal or human bodily material, e.g., fluids, versus delivery of medicament include as examples, allergy screening, e.g., using an electrode mounted array of antigens with a multiplexed-multi-channel application electrode, glucose monitoring and drug testing using electrode mounted specific binders (binder assay) combined with reverse iontophoretic plasma extraction.
- allergy screening e.g., using an electrode mounted array of antigens with a multiplexed-multi-channel application electrode
- glucose monitoring and drug testing using electrode mounted specific binders (binder assay) combined with reverse iontophoretic plasma extraction e.g., body material such as fluids can be extracted into a pad on the electrokinetic device, for example, by reverse iontophoresis.
- Wounds such as scrapes, cuts, burns, plant allergies, punctures and insect bites or stings can be treated with antihistamines, antibiotics, anti-infectives such as bactracin, Diprolene, topical steroids, and the like, aloe or aloe containing products or OTC products such as Ambesol, Lanocaine and the like, other wound healing agents, such as epidermoid derived growth factors as well as peptides that modulate the inflammatory response and modulators of collagen deposition and modeling as well as other wound healing agents all electrokinetically delivered.
- Pre-treatment may also include desensitizing agents such as the aforementioned analgesics or salicylic acid.
- Pruritis, dry skin and keratosis may also be treated using, cortisones and the like, Benadryl itch creme, Lazer creme or EMLA and the like.
- Actinic keratoses may be treated by electrokinetic delivery of aminolevulinic acid as well as other established antimetabolite agents such as methotraxate, 3% DICLOFENAC IN 2.5% hyaluronic acid, 5FU, 5FU and isotretinion, and the like.
- Bursitis or mild arthritis may be treated with magnesium sulfate or Dororac from Genderm.
- a particular use of the device and applicator hereof is the delivery of Acyclovir ⁇ and derivatives and analogs thereof for treatment of recurrent herpetic symptoms, including lesions (oral or genital) and varicella zoster i.e., shingles.
- anti-herpetic medicaments capable of electrokinetic delivery in accordance with the present invention are 5-iodo-2 deoxyuridine (IUDR), cytosine arabinoside (Ara-C), adenine arabinoside (Ara-A), also known as vidarabine, adenine arabinoside monophosphate (Ara-AMP), arabinofuranosyl hypoxanthine (Ara-Hx), phosphonoacetic acid (PAA), thymine arabinoside (Ara-T), 5'-amino-2', 5'-dideoxy- 5-iodouridine (AIU), 1-beta-D-arabinofuranosyl-E-5- (2-bromovinyl) uracil (BV-ara- U), also known as sorivudine, 1 -beta-D-arabinofuranosyl-E-5(2-chlorovinyl)uracil (CV-ara-U), two halogenated deoxyt
- a treatment site is meant a target tissue, e.g., a diseased tissue or diagnostic site for extraction of a substance, underlying or exposed through or on a human individual or lower animal's skin or mucocutaneous membrane including, the eye and also including, but not limited to body cavity and canal sites such as mouth, ear, nose, vagina, and rectum.
- an individual may privately self-administer the medicament by employing the self-powered hand-held device to electrokinetically drive the medicament from an applicator into the treatment site, e.g., through the skin or mucocutaneous membrane to a diseased tissue.
- the self-powered hand-held device to electrokinetically drive the medicament from an applicator into the treatment site, e.g., through the skin or mucocutaneous membrane to a diseased tissue.
- a low-cost throwaway single-use applicator is used to facilitate the flow of medicament into the skin under the influence of the electromotive force supplied to the medicament contained in the applicator by the self-powered hand-held wireless device.
- the hand-held device is preferably lightweight, compact, inexpensive and portable and comprises a housing configured for self-manipulation and containing a power source, for example, a battery, connected through first and second terminals and suitable electronics, including a current driver and voltage multiplier, with active and ground electrodes.
- a power source for example, a battery
- suitable electronics including a current driver and voltage multiplier, with active and ground electrodes.
- the active electrode is preferably mounted on the end of the device to facilitate manipulation of the device so that the active electrode may engage the applicator against the skin or mucocutaneous membrane.
- the second terminal of the power source is connected with the ground electrode, i.e., a tactile electrode, on the surface of the device for electrical contact with a second skin site, i.e., a portion of the individual's hand engaging and manipulating the device.
- self-manipulation is meant that the individual can engage the device in one hand or a portion thereof and freely orient the device to engage the active electrode of the device through the applicator or directly through medicament against the skin or mucocutaneous membrane generally wherever the treatment site is located and irrespective of whether an applicator is used and, if used, irrespective of whether the applicator is attached to the device or to the individual's skin or mucocutaneous membrane or interposed therebetween with the device subsequently applied to the applicator.
- the metal portions of any electrode construction may be of any of a variety of metals or metallic films, foils, screens, deposits, mesh, paints including but not limited to aluminum, carbon, gold, platinum, silver, silver chloride, copper or steel, specifically surgical or similar fine grade steel, titanium, zinc or alloys of the aforementioned materials.
- These metal materials may also be used as a component of an electrode with a plastic base, form or foundation such as Mylar and the like. It is also possible that if the active and ground electrodes are of dissimilar metals or have different half cell reactions the device may generate part or all of its electrical power by this galvanic couple system of which numerous systems are well known in the art and require no further description.
- surfactants to facilitate the rate of hydration may be employed in, on or about the medicament applicator electrode with materials such as the surfactant Tween 20 or 85, made by ICI America, Neodol 91-6, from Shell Chemical Co., Terigol 15-S-7 from Union Carbide, Pluronic Poloxamer F68 or F127 from BASF or Duponol C or XL made by Dupont Chemical Corp or isopropyl myristate.
- surfactant Tween 20 or 85 made by ICI America, Neodol 91-6, from Shell Chemical Co., Terigol 15-S-7 from Union Carbide, Pluronic Poloxamer F68 or F127 from BASF or Duponol C or XL made by Dupont Chemical Corp or isopropyl myristate.
- the applicator preferably comprises a substrate having a reservoir, e.g., an open-cellular structure, for containing a medicament.
- a reservoir e.g., an open-cellular structure
- This preferred open cellular or porous portion forms a minimum barrier to movement of medicament molecules under the influence of the applied current to transport the medicament molecules into the skin or mucocutaneous membrane.
- the applicator thus forms an electrode for application to the treatment site, e.g., an individual's skin and is preferably applied to the device prior to application of the device and attached applicator to the site. It will be appreciated, however, that the applicator electrode can be applied directly to or adjacent to the treatment site, e.g., by using an adhesive, prior to applying the device to the applicator.
- an adhesive is preferably employed, although other types of securement may be used, such as complementary hook-and-loop fasteners, tabs, post and hole, magnets or the like.
- an electrical circuit is completed through the active electrode of the device, the applicator electrode and the treatment site for return through the individual's skin in electrical contact with the ground electrode of the device upon application of the device and applicator electrode to the treatment site.
- an electrical circuit is completed from the device through the applicator electrode, the treatment site, the individual's torso, arm and hand and the tactile electrode.
- the applicator electrode may have a portion, which overlies the tactile electrode to facilitate the flow of electrical current.
- the applicator portion overlying the tactile electrode may be open cellular or porous and may contain an electrically conductive material, e.g., hydrogel.
- an electrically conductive material e.g., hydrogel.
- the material or the tactile electrode may be employed to further facilitate closure of the current loop in any or all applicator or device embodiments.
- the hydrogel may also have adhesive properties or may contain an adhesive and thereby serve or additionally serve as a mechanism for releasably securing the applicator to the device.
- the medicament may be applied to the applicator by the user just prior to use.
- the medicament can be prepackaged as a unit dose in the applicator electrode.
- the medicament also may take many forms, for example, the medicament may be formulated as a liquid, a gel, an ointment, a dry powder, a lotion, a foam, a solution or a cream.
- it may also be electrically conductive perse, or require ancillary substances to transport the medicament, e.g., an electrically conductive substance such as water or very weak trace saline to provide the necessary electrical conductivity.
- the applicator preferably includes a porous or open multi-cellular pad to which medicament can be supplied by the user just prior to use or in which the medicament may be prepackaged.
- the medicament is not sufficiently electrically conductive perse, or is not part of a hydrophilic formulation
- the user may hydrate the pad of the applicator to render the medicament transportable by the electromotive force of the electrical current flowing through the pad.
- the applicator is releasably secured, e.g., by adhesive, to the device.
- the applicator can be applied directly to the skin or mucocutaneous membrane on or surrounding the treatment site, for example, by employing a releasable adhesive or the inherent tack of the substance included with the applicator electrode.
- the medicament can be prepackaged in the pad of the applicator.
- one or more rupturable capsules containing the medicament can be located in or adjacent to the porous pad, the encapsulation of the medicament affording long shelf life.
- the medicament may be prepackaged in or adjacent to the cells of a porous pad with removable seals for preventing exposure of the medicament to ambient conditions thereby also affording long shelf life.
- different applicators can be prepackaged with different medicaments as required for various treatments.
- the capsule or capsules can be ruptured by the application of pressure to the applicator pad, thereby spreading the medicament in and among the interstices of the pad.
- seals are used in conjunction with a medicament contained in a porous applicator pad, the seals are preferably adhesively secured to the pad and removed. If necessary, the pad can then be hydrated by the user. This may be accomplished using a separate small sterile vial of fluid by which drops of solution are applied. The applicator is then applied by the user to the device or to the skin or mucocutaneous membrane overlying the treatment site or simply interposed between the device and the treatment site.
- both the medicament and an electrical conductor such as water can be encapsulated within the pad.
- pressure for example, finger pressure
- the medicament and hydrating capsules can be ruptured, intermingling the medicament and water within or adjacent to the porous multi-cellular applicator pad, rendering the medicament electrokinetically transportable under the influence of the current flow.
- a fourth alternative includes pre-hydrating the pad and sealing the pre-hydrated pad from the medicament. When the seals are broken, the hydrating material hydrates the medicament, enabling electrokinetic delivery of the medicament.
- the medicament may be encapsulated to isolate it from a pre-hydrated pad.
- a sixth alternative is to encapsulate the hydration material, e.g., water or water containing electrolytes to enhance conductivity and medicament transport.
- a seventh alternative is to package the medicament with a hydroscopic material which will allow it to pick up water from the air once it has been removed from its protective packaging.
- the pad containing the electrically conductive medicament or medicament hydrated to afford electrical conductivity through the pad affords a minimum barrier to the movement of the medicament molecules into the treatment site under the electromotive force applied by the completion of the electrical current.
- the substrate or pad is preferably thin and highly porous.
- the pad should be comfortable to the user and if possible be somewhat flexible so as to conform to the treatment site, providing full contact coverage when in place, e.g., fabrics, absorbent gels, cotton or open celled foam.
- the pad should also have sufficient interstices or open cells, i.e., porosity, to hold quantities of the electrically conductive medicament or the medicament and hydrating material to afford efficacious treatment, e.g., of herpes treatment sites, over a period of time, for example, up to 15 minutes. For most treatments, the period of application is limited, for example, within a range of 1-30 minutes.
- the hydrating material is preferably water or a very weak trace saline solution lying within a range of 0.001-0.1%.
- polypropylene glycol, polyethylene glycol or polyvinyl glycol may be used.
- the applicator electrode must be void of any short-circuit paths.
- the applicator includes a hydrogel on an applicator portion overlying the tactile electrode of the device
- the hydrogel must be electrically insulated from the active electrode and the conductive or hydrated medicament in the pad to ensure that the circuit is completed through the individual's skin rather than merely short-circuited through the device and applicator electrode.
- the distance between the medicament containing electrically conductive portion and the hydrogel serves as an electrical insulator, particularly where the substrate therebetween is non-wicking.
- distance between the active and ground electrodes of the device serve the same purpose.
- Additional physical barriers may be provided, e.g., spaces, openings, valleys and ridges of non-conductive material on either or both the device and the applicator electrode. When both are employed they may be of a complementary nature, e.g., a valley on the device and a ridge on the applicator electrode. A portion of the barrier may also be hydrophilic so as to absorb any of the small amounts of hydration material which may be employed.
- the applicator may contain a magnet for activating and deactivating the power supply in the device. Consequently, when the applicator electrode is applied to the device or to the treatment site and the device is applied to the applicator, the magnet cooperates with the intemal electronics of the device to activate the device.
- the magnet in the electrode deactivates the electrical circuit.
- Other conventional switching means may also be employed, e.g., toggle, twist or push types or the magnet may be separate from the applicator.
- the applicator may also contain a code carrying system, e.g., bar code or another state of the art system, which when attached to the hand-held device, programs the device to deliver the correct amount of medicament. This allows the hand held device to be used with a range of medicaments without having to reprogram the hand held unit.
- indicators may be provided on the device to indicate that the device is actuated such that the user can be assured that the medicament is being electromotively driven into the treatment site.
- one or more LEDs may be incorporated in the circuit to indicate activation of the circuit.
- Other indicators or the same indicator in a different mode e.g., solid vs. flashing may be employed to indicate when the device and applicator electrode are operating satisfactorily to electrokinetically drive the medicament into the treatment site.
- An additional indicator can be employed to indicate low battery problems.
- a variable timing device may be incorporated in the electrical circuit. The circuit may be activated for a selected predetermined length of time and automatically deactivated after that time period has lapsed. Alternately, a timer may offer an event signal or series of signals to the user without necessarily reprogramming the time period.
- the timer may continue timing the treatment provided the interruption is only brief, e.g., a minute or two. If the interruption is prolonged, the timer is automatically reset to provide a period of treatment which is therapeutically effective. Also, a non-ultrasound generated vibration can be added or used in lieu of the LED to indicate working status of the device and that the device lies in a closed current loop via the individual's body surface.
- the applicator may comprise a splint-like strip for releasable securement to an individual's finger with self-contained electronics, a power source and active and ground electrodes formed integrally with the strip.
- the applicator strip may have a rectilinear, square, circular or shaped pad as the active electrode adjacent the individual's fingertip.
- the applicator strip preferably includes a split ring for releasably securing the applicator strip to and along an inside surface of an individual's finger.
- the applicator pad which may be integral with or form a disposable pad for the applicator strip, is in contact with the active electrode adjacent the individual's fingertip for application to the treatment site.
- the strip On the opposite side of the strip from the active electrode and in contact with the user's finger is a ground electrode.
- the batteries within the applicator strip may be air-actuated by removal of a tab overlying battery terminals.
- the user places the one-time use disposable applicator pad adjacent the user's fingertip and against the treatment site. This completes the circuit through the site and the user's skin.
- the strip With the applicator pad separate from the applicator strip, the strip may be reusable with other disposable pads. Alternately, the pad may be a built-in part of the strip with or without pre-packaged medicament and/or hydration means, thereby enabling the whole device disposable.
- the applicator may also be miniaturized to the extent that it may have a thimble-like configuration without a ring and may be frictionally retained on the tip of the individual's finger.
- the applicator may comprise a completely self-contained disposable unit having its own electronic circuitry and power source.
- the applicator may be provided (i) without the medicament and electrically conductive material (e.g., water), (ii) with the medicament in a prepackaged form within the applicator requiring only hydration upon use, if the medicament is not perse electrically conductive, or (iii) with both a medicament and hydration material.
- the applicator in this form may comprise a flexible substrate having a medicament pad on a treatment site side thereof, an optional hydration material layer, overlaid by a first electrode, electronic circuitry including a power source, e.g., a battery, a second electrode and, optionally, a conductive material such as a hydrogel.
- the self-contained disposable unit may be removed from its package by the individual upon contact of the individual's finger with a tacky hydrogel exposed on the unit after the package is opened. This finger contact with slight finger pressure may cause contact between the hydration material and the medicament prior to removal from the package. Also, the finger contact and removal from the package further allows highly intuitive manipulation of the unit to the treatment site and ease of use given the lightweight and compact size of the unit.
- the unit may also be placed in a position where the finger contact is replaced by the contact of another grounding site such as would be the case if, by example the unit were placed in the mouth between the gum and inside mucosal tissue of the mouth or if the unit were placed inside the arm and contacted the upper rib cage or if the unit were designed and formed in a fashion similar to a contact lens for ocular treatments. It should be appreciated that the orientation of the active and ground electrodes and placement of the medicament could be reversed in these or other like uses.
- the battery for the circuit for example, a zinc oxide battery, may be of the type activated by exposure to oxygen.
- a tab overlies battery terminals which, when the tab is removed, exposes the contacts to oxygen thereby activating the battery.
- miniaturized power sources may be provided, e.g., film sheet stacked batteries. It will also be appreciated that the medicament may be applied to the applicator pad by the user after the applicator is unpackaged and, if not perse conductive, the pad may also be hydrated by the user prior to application to the treatment site.
- the medicament may be prepackaged within the pad, for example, in one or more rupturable capsules and if not electrically conductive per se, one or more additional capsules containing hydrating fluid, e.g., a conductive fluid, such as water or saline may be prepackaged in the applicator as well.
- a conductive fluid such as water or saline
- the applicator electrode By squeezing the applicator electrode to rupture the capsule or capsules, the encapsulated medicament and, if necessary, the hydrating fluid, intermingle with one another and provide the necessary electrical conductivity through the applicator pad to enable electromotive transport of the medicament through the skin.
- the grounding electrode lies on the opposite side of the applicator from the active electrode and a circuit is therefore completed through the individual's finger or hand holding the applicator over the treatment site and the individual's arm and torso.
- the top or outer portion of the applicator remote from the medicament pad may contain a conductive hydrogel.
- the applicator comprises a self-contained disposable unit likewise having its own electronic circuitry and power source.
- the active electrode may form a portion of the applicator spaced from an electrically insulated ground electrode also forming part of the applicator.
- the applicator is configured such that the first or active electrode of the applicator lies in electrical contact with the applicator pad (electrode).
- the active applicator electrode is applied to the treatment site and the ground electrode on the applicator is placed in electrical contact with the user's skin.
- An electrical circuit is thereby completed through the applicator, the applicator electrode and the treatment site with the return circuit through the skin, and the ground electrode of the applicator.
- the spacing between the active electrode and the ground electrode in electrical contact with the treatment site and the skin, respectively, can be quite small, i.e., on the order of one-half inch.
- the medicament may be formulated as a liquid, gel, ointment, dry powder, lotion, foam, solution or cream.
- the applicator electrode for use with the device may include an electrically insulative housing, for example, a torus, for containing the liquid.
- a microporous film overlaid by a removable barrier, e.g., foil or inert material adhered to the insulated housing to prevent transfer of the liquid within the applicator electrode externally.
- the opposite side of the insulative housing may likewise be confined by a barrier overlying the housing.
- the insulative housing preferably has tabs for attaching the applicator electrode to the device similarly as previously described.
- a conductive plate may overlie the foil or the applicator electrode may be applied to the device directly with the active electrode of the device in electrical contact with the barrier.
- the active and ground electrodes may be spaced one from the other in a self-contained unit and separated by a malleable or tensioned arm.
- the ground electrode may be adhesively secured to the individual at a location adjacent the medicament delivery device and the active electrode placed in contact with the site.
- the springbiased or malleably tensioned arm holds the active electrode with an optional gimbal component in electrical contact with the treatment site in a fully flush or full contact manner, avoiding only partial contact and hence avoiding less than effective treatment. This permits hands' free electrokinetic delivery of the medicament to the treatment site.
- a self-contained unit having its own electronic circuitry and power source for hands' free application to the treatment site.
- a generally U-shaped clip having opposite ends which mount the ground and active electrodes, respectively, as well as the power source and electronic circuitry, may be applied in a gripping or clamping manner to clip the self-contained unit adjacent the treatment site such that the active electrode engages the treatment site for electrokinetic delivery of the medicament.
- electrokinetic medicament delivery may be applied in an ocular applicator similar to and worn like a contact lens.
- the mechanism of the electrokinetic delivery may be multi-channel, for example, as described and illustrated in U.S. Patent No. 5,160,316, now Re. 36,626, incorporated herein by reference.
- a delivery device similar to a contact lens may be employed to therapeutically treat the conjunctiva for acute glaucoma using as an example, Xalatan or even to contour the eye by delivering agents that retain H 0, such as hyaluronidase or hyaluronic acid, which would swell the conjunctiva in specific sites of the eye.
- Antiviral drugs foscamet and ganciclovir either alone or in combination may be electrokinetically delivered for treating herpetic eye infections, e.g., cytomegalovirus (CMV) and CMV retinitis. Differential levels of power and agent delivery are possible with the multi-channel delivery. In this manner, the refraction of the light can be modified by changing or altering the shape of the eye/conjunctiva.
- the medicament delivery device may be worn or applied periodically for various time periods, for example, within a range of 1 to 60 minutes.
- the circuitry limits the maximum current available to the applicator electrode to preferably less than about 1 milliampere per two square centimeters of the skin-contacting surface area of the electrode.
- the current level can vary from about 0.1 to about 1.2 milliamps. While higher currents have been used, user discomfort can be experienced. Buffers could be employed to overcome this milliamp range ceiling.
- the electrical current can be ramped up and ramped down, respectively, at the beginning and end of the treatment. See, for example, prior U.S. Patent No. 5,160,316, now Re. 36,626, the disclosure of which is incorporated herein by reference. Ramping contours of different configurations can be used, for example, linear, non-linear, exponential, pulsed, or otherwise shaped. Also, while direct current is preferred, alternating current can be used.
- facilitators may be employed to minimize or eliminate the barrier to the transfer of the medicament molecules through the skin.
- acetic acid or dimethylsulfoxide (DMSO) alcohols, such as ethanol and isoproanol, ethyalactate ⁇ sulphoxides, fatty acids, such as oleic acid, lauric acid, capric acid and caprylic acid, sodium lauryl sulfate, acyl lactylates (except in their salt form), e.g., caprol lactyic acid and lauroyl lactylic acid, esters, (1-dedecylazacycheptan-2-one) (Azone), pyrrolidones, such as dodecyl pyrrolidone, dimethyl lauramide, linear dialiphatic or aliphathic, sulfoxides, unsubstituted or mono or di-substituted amides and di-substituted amines among
- DMSO dimethylsulfox
- a second facilitator or skin permeation enhancer which may be a monoglyceride or mixture of monoglyerides of fatty acids such as glycerol monolaurate (GML) or glycerol monooleate (GMO), lauramide diethanolamine (LDEA), or esters of fatty acids having from 10 to 20 carbon atoms.
- GML glycerol monolaurate
- GMO glycerol monooleate
- LDEA lauramide diethanolamine
- esters of fatty acids having from 10 to 20 carbon atoms By using these substances, the skin can be disrupted, enhancing the exposure of the dermis to electrokinetic forces.
- Another type of facilitator is a component which may encase a given molecule within a lipid barrier but makes it less polar and thereby facilitates penetration of the skin by the medicament.
- An example is gylcesol or phospholipids such as phosphaticylcholine.
- the device and applicator requires minimal instruction. Where the medicament is prepackaged with the applicator, there are no concerns regarding the dosage as a single unit dosage which is therapeutically effective over the period of application is provided. Moreover, the device and applicator do not require any calibration or settings as the supply of current is fixed by the device electronics. Further, there is no second or ground electrode separate from the device whereby the device is easily used without a separate ground electrode.
- the power source may be limited to providing only single use longevity. Thus, the power supply may be replaced when a device is reused or the device itself may be discarded. Numerous components may be constructed and linked for short life cycle upon use without negating a prior long shelf life. The applicator and even the device per se are readily disposable.
- an applicator for use in an electrokinetic device to deliver substance to a treatment site for an individual, comprising a substrate including a substance-dispensing portion having a first face for electrical contact with an electrode carried by the electrokinetic device and a second face for electrical contact with the treatment site, a reservoir carried by the substrate for containing the substance and including a rupturable barrier for maintaining the substance apart from the substance-dispensing portion, the substance-dispensing portion providing an electrically conductive path through the substrate including at least in part the first and second faces of the substrate for electrokinetically driving the substance into the treatment site upon rupture of the barrier releasing the substance into the substance-dispensing portion and application of the device to the first face and passage of an electrical current through the applicator.
- an applicator electrode for use with an electrokinetic device to deliver a substance to a treatment site for an individual, comprising a substrate having a first surface and a second surface opposite the first surface, the substrate including a substance-dispensing portion comprising a cell or a plurality of cells forming an aperture or a plurality of apertures between the first surface and the second surface, a reservoir carried by the substrate for containing the substance and including a rupturable barrier for maintaining the substance segregated from the substance-dispensing portion, an adhesive layer covering at least a portion of the second surface of the substrate opposite the first surface for releasably attaching the substrate to an electrokinetic device containing an electrical power source for electrokinetically driving the substance through the first surface and into the treatment site upon rupture of the barrier releasing the substance into the substance-dispensing portion and application of an electrical current to effect delivery of the substance in the cell or plurality of cells to the treatment site.
- an electrokinetic delivery device for personal use in self-administration of a substance to a treatment site on an individual comprising a substrate shaped for underlying the undersurface of an individual's finger from a tip thereof to a location past the first finger joint, a self-contained power source within the substrate, a first electrode carried by the substrate and exposed adjacent the tip of the individual's finger, the first electrode being in electrical contact with the power source, a second electrode carried by the substrate and exposed for contact with the individual's finger, the second electrode being in electrical contact with the power source whereby, upon application of the first electrode over a treatment site with the substance disposed between the first electrode and the treatment site, the device applies current for electrokinetically driving the substance into the treatment site.
- a delivery device for self-administration of a substance to a treatment site on an individual, comprising a self-contained disposable applicator including a pad for containing the substance, a power supply, a first electrode overlying the pad and electrically connected to the power supply and a second electrode having a tactile surface in electrical contact with the power supply and lying on a side of the applicator remote from the pad, whereby, upon the individual's hand or a portion thereof in contact with the tactile surface of the second electrode holding the applicator pad against the treatment site, an electrical circuit is completed between the first electrode through the treatment site and the second electrode via the tactile surface and the individual's hand and body for electrokinetically driving the substance into the treatment site.
- a delivery device for self-administration of a substance to a treatment site on an individual comprising a self-contained disposable applicator including a pad for containing the substance and lying on a first side of the applicator, a power supply, a first electrode overlying the pad and electrically connected to the power supply and a second electrode in electrical contact with the power supply and lying on the first side of the applicator whereby, upon application of the applicator pad against the treatment site, an electrical circuit is completed between the first electrode through the treatment site and the second electrode via a portion of the individual's body for electrokinetically driving the substance into the treatment site.
- a medicament-dispensing electrokinetic device for delivery of a medicament to an individual's treatment site, comprising a housing having a portion thereof shaped for manual manipulation by the individual's hand and an electrical circuit including a normally open switch and a first electrode formed of electrically conductive material and exposed for contact with the medicament, the first electrode being mounted for movement relative to the housing between first and second positions, the first electrode closing the normally open switch and completing the circuit in response to movement of the first electrode from the first position toward the second position, a power source forming part of the circuit and contained within the housing, the power source having first and second terminals, the first terminal being in electrical contact with the first electrode, a tactile electrode forming part of the circuit in electrical contact with the second terminal of the power source and having a surface for contact with the individual's skin, the device being operable to electrokinetically drive medicament disposed between the first electrode and the individual's treatment site to effect delivery of the medicament into the treatment site in response to pressing the first electrode toward the
- FIGURE 1 is a schematic illustration of an electrokinetic medicament delivery device for use with an applicator in accordance with the present invention
- FIGURE 2 is a perspective view of the device with the applicator applied thereto;
- FIGURE 2A is a view similar to Figure 2 of a modified form of the device and applicator
- FIGURE 3 is a perspective view illustrating the device and applicator in use by an individual and being applied to a lesion on the individual's chin;
- FIGURE 4 is a plan view of an applicator from the skin side
- FIGURE 5 is a plan view of the applicator from the device side
- FIGURE 6 is an exploded side elevational view illustrating the various parts of the applicator ;
- FIGURES 7 and 8 are views of the applicator pad, respectively, illustrating an encapsulated medicament and a combination of encapsulated medicament and hydration fluid within the applicator pad; ⁇
- FIGURE 9 is a perspective view of a splint-like strip forming a self-contained applicator electrode in accordance with a further embodiment of the present invention.
- FIGURE 9A is a view similar to Figure 9 illustrating a further form of the strip of Figure 9;
- FIGURE 10 is a schematic view of an electrical circuit for use with the applicator electrode of Figure 9;
- FIGURES 11 A, 11 B and 11 C are schematic representations of a self-contained applicator illustrating the layers of the applicator within a packaging material;
- FIGURE 12 is a schematic representation of an applicator in accordance with a further embodiment of the present invention.
- FIGURES 13 and 14 are preferred forms of the applicator of Figure 12 with an encapsulated medicament illustrated in Figure 13 and encapsulated medicament and hydrating fluid illustrated in Figure 14;
- FIGURE 15 is a side elevational view of a further form of the present invention.
- FIGURE 16 is an exploded schematic view of a still further form of applicator electrode in accordance with the present invention.
- FIGURE 17 is a fragmentary view of the applicator of Figure 16 applied to the end of a device
- FIGURE 18 is an illustration of a hands' free electrokinetic medicament delivery device
- FIGURE 19 is a schematic illustration of a still further hands' free electrokinetic delivery device according to the present invention.
- FIGURE 20 is a perspective view of a further form of an applicator, illustrated with its packaging, for use with an electrokinetic delivery device;
- FIGURE 21 is a view of the applicator of Figure 20 without its packaging;
- FIGURE 22 is a schematic illustration of the applicator of Figures 20 and 21 applied to the electrokinetic device
- FIGURE 23 is a perspective view of the device with the applicator applied ready for use
- FIGURE 24 is a schematic representation of an alarm system for misplacement of the probe
- FIGURE 25 is a schematic illustration of an electrokinetic applicator in the form of a sock for treatment of fungal infestations between the toes;
- FIGURE 26 is a view similar to Figure 25 illustrating an electrokinetic applicator for treatment of a nail bed fungal infestation
- FIGURE 27 is a schematic representation of a device for electrokinetically treating a fungal infestation of the nail beds of an individual's fingers
- FIGURE 28 is a schematic illustration of the electronics and thimble pad applicator of the device of Figure 27;
- FIGURE 29 is a schematic representation of a device for electrokinetic ocular treatment
- FIGURE 30 is a side elevational view of an ocular applicator according to this aspect of the invention.
- FIGURE 31 is a planar view of the ocular applicator illustrating the multi-channel conductors.
- the device 10 includes an outer housing 12 containing a power source, for example, a battery 14, and electronic circuitry including a voltage multiplier 16 and a current driver 18.
- battery 14 includes a first terminal 20 and a second terminal 22.
- the first terminal 20 is coupled to the voltage multiplier 16 which steps up the voltage supplied by the battery 14 and applies the stepped-up voltage to the current driver 18.
- Current driver 18 is in contact with a first or active electrode 24 exposed through housing 12, preferably at an end thereof.
- the second terminal 22 is in contact via a spring 26 and a conductor 28, with a ground or tactile electrode 30 also exposed through housing 12, preferably along a side wall thereof.
- housing 12 is sized and configured to be held within an individual's hand for orientation such that the first or active electrode 24 can be in electrical contact with a treatment site through a conductive medicament-containing pad of an applicator, described below.
- the housing 12 may be of a cylindrical form, with the first or active electrode 24 at one end of the cylinder.
- housing 12 can assume other shapes to facilitate the purposes of device 10, namely to provide a portable, self-contained device having an integral power source which, in conjunction with the applicator, may electrokinetically drive medicament through an individual's skin or mucocutaneous membrane into a treatment site when the applicator and device are applied to and overlie the treatment site.
- the housing 12a may have a bend intermediate its opposite ends forming a handle 32 at one end having a tactile ground electrode 30a exposed through the handle. The opposite end terminates in an active or first electrode 24a similarly as in Figure 1.
- the handle 32 forms a grip for orienting and manipulating the device 10a relative to the treatment site.
- the circuitry limits the maximum current available to the applicator to preferably less than about 1 milliampere per two square centimeters of the treatment site-contacting surface area of the applicator. However, depending upon the working surface of the applicator pad in contact with the site, the current level can vary from about 0.1 to about 1.2 milliamps per two square centimeters to avoid minor discomfort and deleterious side effects. These limitations also apply to each channel of a multi-channel device as discussed herein with reference to U.S. Patent No. 5,160,316, now Re. 36,626.
- the hand-held device 10 and 10a may be modified to include a piezoelectric element 19 for imparting ultrasonic vibrational motion to the active electrode 24 to further facilitate transdermal or transmucocutaneous delivery of electrokinetically transportable substances, e.g., medicaments.
- the piezoelectric element 19 is located on the active electrode 24. Power is supplied to energize the piezoelectric element 19 by a conductor 21 connected with the tactile electrode 30, the piezoelectric element 19 being in electrical contact with the active electrode 24.
- An optional switching element may be used to energize the piezoelectric element or not, as desired, depending upon the particular treatment mode.
- applicator 40 having a treatment site-contacting side and a device-contacting side as illustrated, respectively, in Figures 4 and 5.
- applicator 40 includes a substrate 42 formed of a porous open cellular material.
- a suitable substrate material may comprise a fabric manufactured by Cerex of Pensacola, Florida, identified as Type DN, Group DN07&DN15.
- Other suitable types of materials may also be used, provided those materials, at least in the portion of the substrate through which the medicament will be transported to the treatment site, constitute a minimum barrier to the transfer of the medicament molecules from the applicator to the site.
- a pad 44 On the skin or mucocutaneous side of the applicator 40 as illustrated in Figures 4 and 6, there is provided a pad 44 surrounded by a containment barrier 46.
- the pad may likewise comprise a porous open-cellular material similar to the substrate but preferably comprises a more dense material such as cotton for retaining the medicament.
- Cotton is sufficiently porous and open-cellular to enable the medicament to be electromotively driven from the cotton pad into the site. It will be appreciated that the pad 44 should be inert to the medicament, as well as non-corrosive and stable when in contact with the medicament. While cotton is preferred, other suitable materials may include plastic pads such as polyethylene, paper, porous ceramics, open-celled porous polytetrafluoroethylene, polyurethane or other plastics, as well as open-celled silicone rubber and vinyl.
- the containment barrier 46 is formed of a non-electrically conductive material, which prevents the medicament from weeping or wicking onto portions of the substrate adjacent the medicament pad.
- barrier 46 comprises a closed-cell foam, for example, a foam manufactured by Avery Dennison of Pasadena, California, identified as Avery Foam Med 5637. While not shown, the foam is preferably adhesively secured to the substrate 42 with margins of the pad 44 f rictionally or adhesively retained within the peripheral confines of the barrier 46.
- a flap 48 overlies the exposed side of the pad and is preferably adhesively secured along one side to one side of the barrier 46 such that the pad 44 can be exposed by lifting or removing the flap.
- the pad 44 may be incorporated or embedded in the substrate 42. For example, the pad 44 may reside in a cutout portion in the substrate.
- the substrate extends to form wings 52 for releasably securing the applicator to the device.
- a releasable contact adhesive 50 is applied to the applicator wings 52 for releasably securing the applicator to the device 10.
- the applicator 40 illustrated in the form of a strip has a central portion of the strip, i.e., the pad 44, overlying the active electrode 24 at the end of housing 10 with the applicator wings 52 folded along opposite sides of the housing 10 and releasably secured thereto by the adhesive 50.
- a release liner 54 is provided on the device side of the applicator overlying adhesive 50 and which liner 54 is removed by the user upon application of the applicator to the device. It will be appreciated that other methods of releasably securing the applicator to the device may be employed. For example, hook-and-loop type fasteners may be used with the hooks or loops on the device and the loops or hooks on the applicator. Magnets or spring clips or other mechanical-type fasteners may be employed.
- the applicator as illustrated in Figures 4-6 is also illustrated in the form of a strip similar to a Band-Aid. It will be appreciated, however, that other configurations and shapes of the applicator may be employed, depending upon the configuration of the device.
- an applicator 40a having a pad formed of similar material as pad 44 may be employed for use with device 10a of Figure 2A.
- Applicator 40a may be formed in a circular configuration without wings and may be adhesively or otherwise secured to the active electrode 24a of housing 12a.
- the peripheral margin of the applicator 40a may have a releasable adhesive for releasable securement to the active electrode 24a on the end of device 10a.
- the applicator need not have conductive portions overlying the ground electrode 30a.
- the applicator is formed of a flexible material generally conformable to the treatment site surfaces to the extent possible given the shape of the active electrode 24, 24a on the device 10, 10a.
- the applicator 40 is intended for a single use. That is, once the medicament has been electrokinetically driven from pad 44 into the site, the applicator may be removed from the device or the site and discarded. Where the medicament is prepackaged with the applicator, a coloring agent can be employed, such as iodine, which turns color upon contact with the starch in the open-celled material to visibly indicate that unit dose medicament has been used. Other types of coloring agents can be used to indicate usage of the applicator, e.g., pH indicators, wet saturation indicators or oxidizable pigments.
- the applicator may be provided to the user without medicament within the applicator pad 44.
- the user may apply the medicament to the applicator pad 44 such that the medicament lies within the interstices of the material of the pad 44.
- the pad containing the medicament may be hydrated by the application of water, for example, by using an eyedropper.
- the medicament is supplied and prepackaged with the applicator.
- the medicament may be contained within a rupturable polymer reservoir or capsule 56, as illustrated in Figure 7. By encapsulating the medicament, a long shelf-life is assured.
- the capsule 56 can be ruptured by applying pressure to the pad 44, for example, by pressing the pad between the individual's fingers or against the active electrode when the applicator is applied to device 10, or against a surface of packaging in which one or more of the applicators are provided.
- the medicament permeates the interstices of the pad 44. If the medicament requires hydration to afford electromotive transport into the treatment site, e.g., a lesion upon application of the electric current, the user may hydrate the pad similarly as previously described.
- an additional one or more capsules containing hydrating material e.g., water or saline, may be prepackaged with the applicator.
- the pad 44 includes one or more medicament capsules 56 and one or more hydration capsules 58.
- the capsules may be ruptured and the medicament and hydration material intermingled with one another within the interstices of the pad 44, rendering the applicator pad susceptible to conducting current for the electrokinetic delivery of the medicament to the lesion.
- a magnet 60 is preferably incorporated into the substrate 42 on one or opposite sides of the pad 44.
- the electrical circuit in the device may therefore include a magnetic field responsive switch for actuating and deactuating the electrical circuit.
- the circuit is activated and when removed, the circuit is deactivated.
- a conductive gel may be provided within the wings 52 of the porous substrate 42. It will be appreciated that as the applicator electrode is applied to the device 10 ( Figure 2), the wings 52 of the substrate overlie the tactile electrode 30 of the housing 10. The conductive gel thus facilitates electrical conductivity between the individual's fingers or hand overlying the wing portions of the applicator and the tactile electrode 30 to complete the circuit.
- the cells of the substrate on one or both wings 52 may be provided with a conductive substance, e.g., a hydrogel. These wings with hydrogel are electrically insulated from the pad 44 and the medicament.
- electrical insulating barriers may be provided between the pad 44 and the conductive wing or wings. Such barriers may comprise substantial spacing between the pad and wing with non-conductive material therebetween or physical barriers such as openings, ridges or valleys in the substrate portions interconnecting the pad 44 and the one or more wings of conductive material.
- the applicator 40 is preferably applied to the device by aligning the pad 44 with the active electrode 24 on the end of housing 12.
- the wings of the applicator are folded along opposite sides of the device and adhered or held to the device overlying the ground electrode 30.
- the substrate being at least partially open celled, porous, or cutout, e.g., to contain medicament in gel, solution, cream, foam, ointment or liquid form
- the individual's fingers pressing against the substrate and/or the tactile electrode 30 complete an electric circuit path between the device and the individual.
- hydrogel is applied to the wings 52 of the applicator 40, the hydrogel facilitates the completion of the circuit between the individual's hand or finger and the tactile electrode.
- the individual may add water to his/her fingers or hand, thus facilitating electrical conductivity.
- the applicator 40 applied to the device, the device is actuated, for example, by locating the magnet 60 in a position to close the magnetic switch within the electrical circuit.
- a conventional on/off switch may be used in lieu of the magnetic switch.
- the active electrode 24 is also in electrical contact with the medicament containing pad 44 by contact therewith.
- the pad 44 of the applicator is brought into the contact with the treatment site on the individual's skin.
- electrical current flows between the active electrode 24 in the handpiece, through the medicament-containing pad 44 into the treatment site, through the patient's skin, along the torso and arm for return through the finger or hand to the ground electrode 30. Consequently, the medicament is electromotively transported through the individual's skin or mucocutaneous membrane, thus enhancing local delivery of the medicament to the treatment site.
- the applicator 40a may be secured to the end of housing 12a overlying the active electrode 24a or applied to the treatment site.
- the individual holding the device 10a makes electrical contact with the ground electrode 30a of the handle 32 by grasping the handle. To ensure good electrical contact, the individual may also add water to his/her fingers or hand.
- the device 10a is then manipulated to contact the active electrode 24a through the applicator 40a with the treatment site thereby completing the electrical circuit similarly as in the embodiment of Figure 2.
- the device perse may also be applied to a treatment site without a medicament, e.g., without use of the applicator 40 or 40a.
- the current delivered to the treatment site by the device alone or with or without ultrasonic application or enhancement has beneficial and healing effects in the treatment of the various maladies noted previously.
- the self-contained unit includes a semi-flexible substrate 72, for example, formed of a plastic material, for underlying an individual's finger and shaped according to the inside surface of an individual's finger.
- the substrate 72 passes along one or more of the finger joints.
- the substrate 72 includes batteries 74, for example, conventional zinc oxide batteries which may be actuated by removal of a tab exposing battery contacts to the atmosphere.
- the substrate 72 includes electronics 76 for supplying a flow of current to an active electrode 78 carried at the fingertip end of the substrate 72 and angled relative to the linear extent of substrate 72.
- the active electrode 78 is electrically coupled to the electronics 76 and batteries 74.
- a ground electrode is electrically coupled to the other terminal of batteries 74 and is electrically insulated from the active electrode 78.
- the ground electrode 80 may comprise a flexible material, portions of which may be in the form of a split ring 82. Thus, the full length of the individual's finger may be in contact with the ground electrode, affording a good electrically conductive contact therewith.
- a retainer for example, a retaining strap 73
- a retainer is provided adjacent the inner end of the substrate 72 to, in addition to the split ring 82, releasably secure the applicator electrode to the individual's finger.
- the retaining strap 73 may include semi-rigid arcuate split ring portions, a full ring integral with substrate 72 or a flexible strap with fasteners to secure the strap ends to one another, for example, hook-and-loop type fasteners.
- a similar self-contained unit 70a is illustrated in Figure 9A wherein like parts are designated by like reference numerals followed by the suffix "a."
- the substrate 72a extends along the underside of an individual's finger but only along the finger from its tip, past the first joint and terminating short of the second joint.
- substrate 72a includes batteries 74a, electronics 76a, an active electrode 78a at the fingertip, and a ground electrode 80a including split ring 82a. Additionally, the tip 71 of the substrate 72a may curve back over the fingertip to assist in securing the substrate to the fingertip.
- the electronic circuitry for the applicator electrodes 70 and 70a of Figures 9 and 9A is illustrated in Figure 10 and which circuitry is applicable to all embodiments hereof.
- the power supply for the device 70 includes an air-activated battery 74, coupled through a voltage booster 75 by way of an optional low battery indicator 77.
- the air-activated batteries may be replaceable and other types of small batteries, such as lithium disks, could be used.
- the voltage booster 75 is connected to a servo controlled current source 79 and, optionally, to a current monitor 81.
- the current source 79 is electrically coupled to a current limiter 83 for limiting the current applied to the active electrode within the limits previously discussed.
- the current limiter 83 is coupled to the treatment electrode 78.
- the treatment electrode is illustrated as applied to the treatment site, e.g., a lesion, through a medicament pad 44a.
- the ground electrode is also illustrated as applied to the skin by way of an optional electrically conductive hydrogel 85.
- the medicament pad 44a may be releasably or permanently secured to the device 70, preferably in overlying relation to the active electrode 78.
- the device 70 may be a one-time-use disposable or, if the pad is separate, the device 70 may be reused with additional pads.
- the overlying pad 44a may contain a prepackaged medicament M or any of the alternative combinations of pad, medicaments and hydration disclosed in this application. Alternatively, the pad 44a may be provided in a separate package with the medicament in capsulated form as previously described.
- the medicament pad is applied between the active electrode 78 and the treatment site.
- the power supply is activated. This may be accomplished when opening the packaging or upon removal of the device from the packaging.
- the active electrode 78 is placed in contact overlying the treatment site surface, the circuit is completed through the individual's body, including the finger in contact with the ground electrode.
- the applicator 70 is preferably a single-use applicator which may be discarded after use.
- the substrate 72 may be shaped in the form of a thimble for overlying the entirety of the fingertip of the individual.
- the electronics 76 and batteries 74 may be formed on the back side of the thimble opposite the side containing the active electrode, with the ground electrode lying along the inside surface of the thimble and electrically insulated from the active electrode.
- the applicator hereof comprised of a completely self-contained disposable unit or applicator 90 integrally containing the electronic circuitry and a power source.
- the applicator is prepackaged for one-time usage.
- the applicator 90 comprises a pad 92 for containing the medicament and, if necessary, a hydrating fluid.
- the first active electrode 94 electrically connected to electronics 96 within the applicator and which electronics 96 includes a power supply, for example, a battery, and the necessary electronics for flowing a current of a magnitude previously discussed through the pad to electrokinetically drive the medicament into the treatment site.
- a ground electrode 98 Overlying the electronics is a ground electrode 98, the surface of which remote from pad 92 comprises a tactile surface. Illustrated by the dashed lines is a packaging material 100, for example, plastic packaging typically employed for sterilized packages whereby the applicator 90 may be sealed within the material 100. With the medicament prepackaged within the pad 92, the user opens the package 90.
- the applicator 90 is connected with the packaging 100 via a tab 102. By removing the applicator 90 from or opening the packaging material 100, the tab 102 uncovers the battery terminals whereby the power supply is activated. In Figure 11 A, the applicator is provided without the medicament.
- the user applies the medicament to the pad, hydrates the pad if necessary, and applies the applicator to the treatment site.
- an electrical circuit is completed through the individual's finger and body and through the first electrode, the pad and treatment site whereby the medicament within the pad is electromotively transported to the site.
- the ground electrode may have an electrical conducting fluid, e.g., hydrogel, overlying its tactile surface.
- both the medicament and the hydrating fluid is self-contained in the pad.
- the medicament and the hydrating fluid can be provided in capsules rupturable by pressure applied between the opposite surfaces of the pad before, during or after removal of the applicator from the package 100.
- a very weak, e.g., less than 0.05% saline solution encapsulated and integrated between the active foil electrode 94 and the medicament with or without a porous matrix reservoir interposed between the encapsulated hydration fluid and the medicament may be employed.
- adhesively attached or otherwise releasably attached seals for sealing the medicament and the hydration fluid, if necessary, to the applicator to ensure long shelf life and integrity of the foil electrode can be provided.
- the unit of Figures 11A-11 C may have a tacky substance, e.g., hydrogel, not shown, overlying the ground electrode 98 within the package 100.
- a tacky substance e.g., hydrogel, not shown
- the individual may contact his/her finger on the tacky substance, facilitating removal of the unit from the package 100.
- This finger contact on the ground electrode side of the unit also facilitates ready, direct and intuitive manipulation and application of the unit to the treatment site by the individual.
- applicator body or substrate 110 which comprises a self-contained disposable unit having integral miniaturized electronic circuitry and a power source.
- the applicator may comprise a rectilinear or circular article having a centrally located pad 111 and electronic circuitry superposed over the pad.
- a first or active electrode 112 overlies the pad and the electronics previously described may overlie the first electrode.
- the battery 116 may overlie the electronics.
- the first terminal of the battery is connected through the electronics with the first electrode which, in turn, is in electrical contact with the pad 111.
- the second terminal of the battery is in contact with a ground electrode 118.
- the ground electrode may be provided around the margin of the applicator surrounding the pad.
- the ground electrode may comprise an annulus surrounding and electrically insulated from the pad 111.
- the ground electrode may comprise the margin of the rectilinear applicator or lie at one end of the applicator.
- the electrical circuit is completed between the ground electrode and the pad.
- the distance between the ground electrode and the pad may be on the order of one-half inch or more.
- the ground electrode need not surround the pad but may be located to one side of the pad a suitable distance from the pad for completing the return circuit path through the skin between the treatment site and the ground electrode.
- the pad may be provided without the medicament and the user may apply the medicament to the pad upon removal of release liner 120.
- the battery may be of the air-actuated type previously discussed.
- the user upon applying the medicament to the pad and removing the tab from the battery, may apply the applicator over the lesion, holding both the ground electrode about or spaced from the treatment site and the pad in contact with the treatment site. This completes the electrical circuit through the applicator and the individual's skin between the ground contacting surface and pad contacting surface.
- adhesive may be provided on the underside of the applicator body 110 and overlaid by the release liner 120 to releasably adhere the applicator including the pad 111 and ground electrode 118 to the individual's skin and overlying the treatment site. Upon completion of the treatment, the applicator may be discarded.
- the applicator may be prepackaged with the medicament encapsulated within the pad.
- the capsule is indicated at 122. If the medicament is itself electrically conductive, the individual may apply pressure to the pad to rupture the capsule, spreading the medicament into the interstices of the pad. This can be accomplished while the applicator remains in its packaging.
- the circuit is completed whereby the medicament is electrokinetically driven into the site.
- both the medicament and a hydrating fluid are encapsulated in the pad.
- the medicament and hydration fluid capsules are indicated at 122 and 124, respectively.
- the applicator of Figure 14 is employed similarly as described with respect to Figures 12 and 13 after the user ruptures the capsules to intermingle the electrically conductive water and the medicament.
- FIG 15 there is illustrated a device 130 similar to the device of Figure 1 and containing a power source, electronic circuitry including a voltage multiplier and a current driver and a tactile electrode 132 exposed through an outer surface of the device 130.
- the active electrode 134 is mounted on the device 130 for movement in an axial direction.
- the movement is designed to open or close a pressure actuated switch in the electronic circuitry to activate the device.
- the active electrode 134 in an outermost position maintains the electronic circuitry in an off condition.
- Pressure applied to the first or active electrode 134 tending to displace it toward the device housing closes the switch, activating the electronic circuitry for electrokinetic delivery of the medicament.
- the distal face of the first electrode 134 may be provided with an electrical insulator ring 136 defining and surrounding a reservoir 138.
- the medicament can be supplied from an ancillary tube, jar or the like in the form of a gel, cream, foam or the like and disposed by the user into the reservoir 138 within the insulating ring 136 prior to use.
- the device With the reservoir filled with medicament, the device can be applied to the treatment site similarly as the device of Figure 2 is applied to the treatment site. By applying a slight pressure on the device toward the treatment site, the electrical circuit is closed.
- the medicament within the reservoir is electrokinetically motivated into the treatment site, the electrical circuit being completed through the treatment site, with the medicament, the first electrode 134, the electronics, the tactile electrode 132 and the individual's hand and skin between the tactile electrode and the treatment site.
- an applicator generally designated 150, may be used in conjunction with the device illustrated in
- the applicator 150 may comprise an insulated annular housing 152 in the form of a torus having a central reservoir 154 for confining the liquid.
- One side of the housing 152 comprises a microporous film 156 overlaid by a barrier, e.g., foil or inert tab 158.
- the margin of the tab 158 has releasable adhesive 160 such that the barrier can be releasably attached to one side of the housing 152.
- the barrier tab includes a finger tab 162 for ready removal of the barrier 158 from the applicator.
- the opposite end of the reservoir 154 is closed by a similar barrier layer 164 or by an optional conductive plate 166. Additionally, tabs 168 are secured along opposite sides of the housing 152 for releasably securing the housing 152 to the device, e.g., illustrated in Figure 1.
- the active electrode of the device bears against the optional conductive plate 166 which conducts electricity through the barrier layer 164 into the liquid medicament in the reservoir 154.
- the liquid medicament when applied to the treatment site can be electrokinetically driven into the treatment site through the microporous film 156.
- the liquid within the reservoir may be perse conductive or, if not conductive, may be provided with a carrier whereby the medicament can be driven through the porous membrane 156 into the treatment site.
- the ground electrode and the active electrode are separated one from the other by a malleable or tensionable arm 180.
- the ground electrode 182 may be provided in a housing also containing the battery 184 and electronics 186.
- the ground electrode 182 may be surrounded by an adhesive 188 for adhering the ground electrode to a site on an individual directly adjacent a treatment site.
- the active electrode 190 is connected to the battery and electronics via an electrical conductor indicated by the dashed lines 192 through an arm 180.
- the arm may be flexed resiliently and retained in its flexed position.
- the ground electrode is adhered to the individual's skin adjacent a treatment site by the adhesive 188.
- the arm 180 is then flexed resiliently to engage the active electrode 190 with the treatment site.
- the entire surface of the active electrode 190 may contact the treatment site thereby avoiding less than effective treatment.
- a biased gimbal or pivotal connection between the arm 180 and the ground electrode 182 may also be employed rather than a resilient flexible arm 180.
- the user may apply the device and have it operate hands' free, the electronics being activated by activation of the battery as previously described.
- a similar type of hands' free electrokinetic medicament delivery device is illustrated in the form of an U-shaped clip.
- the ground and active electrodes 192, 194 are placed at opposite distal ends of a clip 196, preferably a spring clip.
- a clip 196 By placing the electrodes on the inside of the clip, the clip may be applied to gently grip the treatment site, employing the tension of the clip to retain the clip on the treatment site whereby hands' free delivery of the medicament can be accomplished.
- the fully disposable U-shaped clip may have a built in unit dose applicator or may be reusable if fitted out for use with disposable applicators.
- Applicator 200 for use with an electrokinetic delivery device 202 ( Figures 22 and 23) illustrated in a flat configuration and within packaging 204, for example, a plastic sealed package.
- Applicator 200 includes a flattened sleeve 206 open at its opposite ends and having an applicator pad 208 forming part of the sleeve and projecting from one end of the sleeve and along an edge thereof.
- the applicator pad 208 is circular in form, for reasons which will become apparent and is hinged to sleeve 200 along a hinge line 209.
- the pad 208 is preferably a porous open cellular material through which the medicament may be transported to the treatment site.
- the pad 208 may contain the medicament within the pad within the interstices of the open cellular material or the medicament may be encapsulated within rupturable capsules 210, similarly as illustrated with respect to Figures 7 and 8.
- a further alternative provides a pad without medicament, the medicament, and hydration material, if necessary, being applied to the pad by the user at the time the user employs the device to electrokinetically deliver the medicament to the treatment site.
- the pad 208 may additionally contain hydration material in a hydration capsule 21 similarly as illustrated in Figure 8 in the event the medicament is not perse electrokinetically transportable.
- the sleeve 206 is preferably formed of a fabric material similarly as the material of substrate 42.
- suitable materials may be employed forming all or part of the sleeve, i.e., the substrate of any of the applicators disclosed herein may include, polyethylene, paper, cotton, ceramic, silicone rubber, polyurethane, vinyl, polytetrafluoroethlene and other plastics.
- a suitable barrier may be disposed between the pad 208 and the sleeve 206 to prevent migration of the medicament onto the sleeve or migration of any electrically conductive material such as hydrogel as noted below from the sleeve 206 onto the pad 208.
- Opposite sides of the sleeve 200 may have cutouts 214 which open through the end of sleeve 206 opposite the pad 208 or which may be completely enclosed cutouts. Particularly, the cutouts 214 lie at circumferential positions about the sleeve 206 corresponding to the axial and circumferential positions of the tactile electrode, for example, electrode 30 as illustrated in Figure 1. Additionally, a tab 216, preferably having a pressure sensitive adhesive on one face, projects from the pad 208 opposite from its connection with the sleeve 206.
- the packaging 204 is removed from the applicator 200.
- the pad may be compressed between the individual's fingers to rupture the capsule 210 and hence spread the medicament into the interstices of the pad.
- the hydration capsule 212 is likewise ruptured to mix the medicament and hydration material such that upon application of electric current, the medicament may be transported to the treatment site. If, of course, the medicament has previously been applied to the pad, the user need not compress the pad. Alternatively, if the pad contains no medicament, the user may apply the medicament to the pad and hydration material, e.g., water or a trace saline solution, if necessary.
- the sleeve 206 may have, instead of cutouts 214, areas impregnated with hydrogel to facilitate electrical contact between the individual's fingers and the tactile electrode of the electrokinetic delivery device.
- auxiliary hydration material e.g., water may be employed.
- the sleeve may also contain magnetic switch activation material.
- the above mechanisms may be monopolar or multi-channel (as in U.S. Patent No. 5,160, 316, now Re. 36,626, incorporated herein by reference), or hybrid multi-channel in nature.
- hybrid multi-channel it is meant that only one current driver is employed while more than one current limiter is employed to a corresponding number of two or more current distributive channels.
- electrokinetic devices e.g., iontophoretic devices
- iontophoretic devices is non-uniformity in contact pressure between the treatment surface and the active electrode surface. For a self-medicating patient using a probe-type iontophoretic device, if the probe is accidentally held at an oblique angle, non-uniform contact pressure occurs.
- the local electric resistance is low and therefore more current flows in this small area.
- the resulting current concentration not only prevents a uniform delivery of medicament but also can cause discomfort and even burns due to a high local current density. This detrimental occurrence can be prevented (for example, by using a multi-channel design (segmented electrode).
- a multi-channel design segment varies. For small changes in contact pressure and resistance, the current flowing in each channel remains constant due to servo control.
- the bias potential or voltage of each channel will change. For an area with higher contact pressure, and therefore lower resistance, the bias potential will decrease. Based on this decrease in bias potential, an early warning signal for uneven probe placement can be generated and transmitted to the patient for readjustment. If this warning is ignored, and the pressure concentration deteriorates further, some channel will reach its maximum bias potential limit and the current and the concomitant medicament delivery will decrease from the pre-set level. For the channels where the contact pressure is high and resistance is low, the current remains constant (due to servo control of the current) in spite of the reduction in resistance. This is one of the benefits of a multi-channel system where current density remains unchanged under each segmented electrode. The non-uniform contact pressure can still cause global non-uniform medicament delivery but not burns.
- FIG. 24 An example of how the presence of non-uniform contact pressure can be detected is illustrated in Figure 24.
- the treatment electrode is divided into four segments 25a-d as shown in Figure 24.
- Treatment currents in equal amounts, flow to electrode segments 252a-d, respectively.
- the current components are maintained by separate servo control loops to remain constant, irrespective of the skin and medicament conductivity, by varying the bias potential of each electrode segment.
- the bias potentials, Va, Vb, Vc and Vd for respective segments are substantially equal.
- the bias potential of each segment is connected to an analog multiplexer 254, the output of which is, in turn, connected to an analog-to-digital (A-to-D) channel of a micro-controller 256.
- Micro-controller 256 is an IC including a microprocessor core with digital inputs, outputs, A-to-D converter, timer, and other functional elements.
- the microprocessor can be programmed to conduct many diverse tasks. It can also be programmed, for example, to periodically measure and compare the bias potential of each electrode segment.
- the electrokinetic probe may be determined to be tilted downward by the patient such that the contact pressure is higher under segments C and D, and lower under segments A and B.
- the micro-controller can cause an alarm 258 to output an aural and/or visual alarm when the non-uniformity in contact pressure (as determined from the bias potentials) exceeds some predetermined value.
- the non-uniform pressure detection can also be accomplished by using discrete analog circuitry with operational amplifiers, comparators etc.
- the infections afflict age groups from childhood to late adulthood and the aged and immune suppressed population.
- the infections may include, for example, diaper rash, athlete's foot or jock itch and, in children, ringworm and other dermatophytosis.
- the current treatment of such infections involve anti-fungal agents applied topically. In healthy patients, the topical treatment works, although sometimes frustrating in its response time and chances for recurrence.
- the present invention offers a more rapid resolution of topical infections and more effective non-systemic treatment of the more refractory nail infections.
- the treatment method and apparatus for fungal infestation employs an electrokinetic, e.g., iontophoretic transport mechanism including electronics to drive the medicament into the infected (treatment) site to ultimately prevent the fungus from replicating.
- electrokinetic e.g., iontophoretic transport mechanism including electronics to drive the medicament into the infected (treatment) site to ultimately prevent the fungus from replicating.
- iontophoretic transport mechanism including electronics to drive the medicament into the infected (treatment) site to ultimately prevent the fungus from replicating.
- medicaments available on the market for this purpose.
- non-pharmaceutical level agents that may have a significant benefit to the treatment of fungal infections.
- an applicator 270 for the treatment of athlete's foot, e.g., where fungal infestation occurs between the toes.
- the applicator 270 is in the form of a flexible elastic sock electrode with an electronics package 271 containing a battery 272, electronics 274, ground electrode 276 and active electrodes 278 in registration with fungal infested areas between the individual's toes.
- the package 271 is strapped about the individual's ankle by a strap 273.
- Discrete medicament-carrying pads 280 are shaped to extend between the toes along the interior potion of the toe region of the sock.
- Individual branch wires 284 overlying the pads 280 and with an electrically insulative covering, not shown, are coupled to the electronics package by conductive wire leads 285 disposed in an insulative protective ribbon 286.
- a single treatment is sufficient to drive the anti-fungal medication carried by the pads 280 into the infected area between the toes to completely resolve the fungal infestation.
- the pads may form an integral part of the elastic sock 270 preferably along the inside portion of the toe region.
- the medicament is preferably pre-supplied within the pads, e.g., encapsulated and with or without hydration material as in prior embodiments hereof.
- the sock 270 may also be disposable with the electronics package 271 or the electronic package may be disconnected and reconnected to one or more additional socks as needed for applying additional medicament at the appropriate treatment intervals.
- the elastic sock 290 includes active electrode portions 292 overlying a pad 293 containing the anti-fungal agent in the region of the sock overlying the individual toenails.
- Each active electrode portion 292 may comprise short individual lead wires 294 coupled via individual leads 296 to an electronics package 298 similar to the package described and illustrated with respect to Figure 25.
- electrokinetic delivery of the medicament to the nail beds of the toes is provided upon completion of the circuit through the active electrodes 294 and ground electrode in the electronics package 298 through the ankle of the individual.
- This treatment requires prolonged and overnight wear of the sock electrode and may involve a plurality of treatments, for example, three treatments with a spacing of about two or three days.
- an applicator body 300 may be generally hemispherical in shape and is preferably formed of a resiliently elastic material.
- an applicator body 300 In the arcuate surface of the hemispherically-shaped body 300, there is provided one or more fingerholes 302 into which the individual's fingernails may be received, e.g., up to about the first finger joint. .
- five fingerholes 302 can be provided at various positions about the body 300 consistent with the anatomical orientation of an individual's bent fingers when his/her hand rests on the arcuate upper surface of the body 300 enabling the fingertips to be received in the openings 302.
- the body 300 includes an active electrode 304 in each of the openings 302 at a location in registration with, i.e., opposite, the fingernail of the individual's finger when received in the hole.
- a medicament-containing porous pad for example, in the form of a thimble 306, preferably pre-supplied with medicament or having encapsulated medicament along a forward edge thereof is provided.
- the individual user may apply the medicament to the thimble pad portion upon use.
- the thimble 306 may also contain a resilient elastic material 308, for example, sponge material, such that upon placing the thimble about the individual's fingertip and the fingertip including thimble 306 in the hole 302, the sponge material 308 biases the individual's nail forwardly into contact with the forwardmost pad portion of the thimble to make electrical contact with the active electrode 304.
- hydrating material may also be supplied integrally with the thimble, for example, in the form of encapsulated hydration material or the individual may hydrate the medicament in the thimble pad portion upon use.
- the ground electrode 310 is provided along an arcuate surface of the body 300 such that when the individual lays his/her hand over the arcuate portion of the body 300, the palm of the hand rests against ground electrode 310 with the finger or fingers in the holes 302 bearing against the pad 306 and active electrodes 304.
- each hole 302 has an active electrode 304 associated with that hole.
- the active and ground electrodes are coupled to the electronics 312 which, in turn, is coupled to a power source 314 integral with body 300.
- the body 300 may have other shapes, for example, an elastic spherical shape, such that the individual can carry the electrokinetic delivery device in his/her hand for the duration of the treatment period.
- the body 300 may have a flat undersurface enabling the individual to rest his/her hand on the upper arcuate surface of the body 300 with body 300 supported, for example, on a desk or table.
- active electrodes can be designed for size and contour for application to various parts of the human body.
- electrodes can be woven into undergarments to alleviate refractory infestation in the inguinal area, commonly described as jock itch.
- applicators such as the sock electrodes described, are disposable items with prescribed medication pre-supplied for specific application.
- various medicaments may be electrokinetically applied in an ocular application similar to and worn like a contact lens.
- an electronics package 320 comprised of a battery 322, electronics 324 and a ground electrode 326 carried by a strap 328 designed to envelope the individual's head releasably securing the electronics package 320 on the forehead with the ground electrode engaging the individual's forehead.
- the mechanism of the electrokinetic delivery may be a multi-channel electrode as described in U.S. Patent No.
- the electronics of the package 320 are coupled to an applicator electrode 330 for each eye via a ribbon cable connector 332.
- the applicator electrodes 330 are each in the form of a concave-convex matrix formed of electrodispersive material sufficiently flexible to fit and overlie the various contours of individual eyes. Each matrix is similar to a contact lens.
- Applicator electrode 330 includes a combined handle and connector 334 which projects from the convex side of the applicator electrode 330, facilitating a finger grip for the contact electrode 330 and an electrical connection for the ribbon connector 332. The individual lead wires in the ribbon connector 332 are continued through the combined handle and connector 334 into the electrode 330.
- these individual conductors or lead wires 336 extend from the combined handle and connector 334, preferably in semi-circular patterns along opposite halves of the contact electrode 330.
- Each of the conductors 336 has a plurality of short lead wires or supplemental conductors 338 at spaced positions along each connector 336 to provide increased contact area, i.e., to further distribute the electrical current flow along the surface of the eye.
- Each of the lead wires or connectors 336 has a discrete pad 339 associated with it for carrying the medicament and which medicament is electrokinetically driven into the eye upon completion of the electrical circuit between the applicator electrode 330, the eye, the individual's skin between the active and ground electrodes, and the ground electrode 326.
- the lead wires 336 in each contact electrode 330 may be electrically driven simultaneously or in sequential multiplex fashion.
- the current in each connector 336 being limited, for example, within the range previously discussed, current tunneling or current flow along the path of least resistance is substantially eliminated.
- the ocular electrokinetic delivery system described herein is preferably worn by an individual over a period of time, for example, up to an hour, with the multi-channel driver electrokinetically delivering the medicament into the cornea.
- the contour of the eye can be reshaped by delivering agents that retain water which would swell the conjunctiva in specific sites of the eye.
- the refraction of light can be modified by altering the shape of the eye.
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR0111288-0A BR0111288A (en) | 2000-05-31 | 2001-05-21 | Electrokinetic Supply Device |
CA002413806A CA2413806C (en) | 2000-05-31 | 2001-05-21 | Electrokinetic delivery device |
JP2001587863A JP4199457B2 (en) | 2000-05-31 | 2001-05-21 | Electrodynamic supply device |
AU2001274851A AU2001274851B2 (en) | 2000-05-31 | 2001-05-21 | Electrokinetic delivery device |
EP01941502A EP1294438A4 (en) | 2000-05-31 | 2001-05-21 | Electrokinetic delivery device |
AU7485101A AU7485101A (en) | 2000-05-31 | 2001-05-21 | Electrokinetic delivery device |
MXPA02011842A MXPA02011842A (en) | 2000-05-31 | 2001-05-21 | Electrokinetic delivery device. |
HK03106645.3A HK1054338A1 (en) | 2000-05-31 | 2003-09-16 | Electrokinetic delivery device |
AU2005225129A AU2005225129B2 (en) | 2000-05-31 | 2005-10-24 | Electrokinetic delivery device |
AU2007231635A AU2007231635A1 (en) | 2000-05-31 | 2007-10-24 | Electrokinetic delivery device |
AU2010201975A AU2010201975A1 (en) | 2000-05-31 | 2010-05-17 | Electrokinetic delivery device |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/584,138 US6477410B1 (en) | 2000-05-31 | 2000-05-31 | Electrokinetic delivery of medicaments |
US09/584,138 | 2000-05-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001091853A1 true WO2001091853A1 (en) | 2001-12-06 |
Family
ID=24336071
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/016069 WO2001091853A1 (en) | 2000-05-31 | 2001-05-21 | Electrokinetic delivery device |
Country Status (11)
Country | Link |
---|---|
US (5) | US6477410B1 (en) |
EP (2) | EP1294438A4 (en) |
JP (1) | JP4199457B2 (en) |
CN (1) | CN1287877C (en) |
AU (5) | AU2001274851B2 (en) |
BR (1) | BR0111288A (en) |
CA (1) | CA2413806C (en) |
HK (1) | HK1054338A1 (en) |
MX (1) | MXPA02011842A (en) |
RU (1) | RU2268075C2 (en) |
WO (1) | WO2001091853A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003234691B8 (en) * | 2002-04-08 | 2003-10-27 | Biophoretic Therapeutic Systems, Llc | Finger-mounted electrokinetic delivery system |
FR2844719A1 (en) * | 2002-09-24 | 2004-03-26 | Francois Duret | Electro-chemical whitening device for dental or medical use comprises electric, electrophoretic or electromagnetic field generator with associated whitening agent application and activation means |
EP1418919A2 (en) * | 2001-07-20 | 2004-05-19 | Iomed, Inc. | The use of 5 fluorourcil, delivered by inotophoresis as an inhibitor of cell proliferation in the eye, bulbar and palpebral conjunctiva, eyelid, peri-orbital soft tissues and skin |
WO2004105864A1 (en) * | 2003-06-03 | 2004-12-09 | Eyegate Pharma S.A. | Ocular device for current controlled variable delivery of active principles |
AU2005225129B2 (en) * | 2000-05-31 | 2007-07-26 | Biophoretic Therapeutic Systems, Llc | Electrokinetic delivery device |
AU2007203591B2 (en) * | 2002-04-08 | 2010-07-29 | Biophoretic Therapeutic Systems, Llc | Finger-mounted electrokinetic delivery system for self-administration of medicaments |
WO2014164842A1 (en) * | 2013-03-11 | 2014-10-09 | Birchwood Laboratories, Inc. | Sweat analyte testing components and methods |
EP2474281B1 (en) * | 2003-12-24 | 2019-03-27 | The Regents of The University of California | Tissue ablation with irreversible electroporation |
US10518073B2 (en) | 2006-06-15 | 2019-12-31 | Polypharma Pty Ltd | Delivery system and process |
EP2996756B1 (en) * | 2013-05-15 | 2020-12-16 | Solvamed GmbH | Skin applicator for applying highly volatile substances |
US11806163B2 (en) | 2018-10-09 | 2023-11-07 | Inter.mix, Inc. | Hydration testing article |
Families Citing this family (308)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110075507A1 (en) * | 1997-10-24 | 2011-03-31 | Revalesio Corporation | Diffuser/emulsifier |
US6702949B2 (en) | 1997-10-24 | 2004-03-09 | Microdiffusion, Inc. | Diffuser/emulsifier for aquaculture applications |
US7127285B2 (en) * | 1999-03-12 | 2006-10-24 | Transport Pharmaceuticals Inc. | Systems and methods for electrokinetic delivery of a substance |
US6641591B1 (en) | 1999-08-26 | 2003-11-04 | John H. Shadduck | Instruments and techniques for controlled removal of epidermal layers |
US6544555B2 (en) | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
US6565882B2 (en) * | 2000-02-24 | 2003-05-20 | Advancis Pharmaceutical Corp | Antibiotic composition with inhibitor |
US20040111050A1 (en) * | 2000-04-14 | 2004-06-10 | Gregory Smedley | Implantable ocular pump to reduce intraocular pressure |
US20050049578A1 (en) * | 2000-04-14 | 2005-03-03 | Hosheng Tu | Implantable ocular pump to reduce intraocular pressure |
US20020068078A1 (en) * | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
US6541014B2 (en) * | 2000-10-13 | 2003-04-01 | Advancis Pharmaceutical Corp. | Antiviral product, use and formulation thereof |
US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
US7488303B1 (en) * | 2002-09-21 | 2009-02-10 | Glaukos Corporation | Ocular implant with anchor and multiple openings |
US20020189947A1 (en) * | 2001-06-13 | 2002-12-19 | Eksigent Technologies Llp | Electroosmotic flow controller |
US7465382B2 (en) * | 2001-06-13 | 2008-12-16 | Eksigent Technologies Llc | Precision flow control system |
US8788031B2 (en) * | 2001-09-21 | 2014-07-22 | Encore Medical Asset Corporation | Method and device for the iontophoretic delivery of a drug |
FR2830766B1 (en) * | 2001-10-12 | 2004-03-12 | Optis France Sa | DEVICE OF ISSUE OF DRUGS THROUGH IONTOPHORESIS TRANSPALPEBRALE |
JP4394444B2 (en) * | 2001-10-24 | 2010-01-06 | パワー ペーパー リミティド | Devices and methods for controlled intradermal delivery of active agents |
US20030144625A1 (en) * | 2002-01-28 | 2003-07-31 | Garry Sherman | Method and apparatus for the treatment of infections of the nail matrix and nail plate |
US7483736B2 (en) * | 2002-04-24 | 2009-01-27 | Rocky Mountain Biosystems, Inc. | Feedback control device for transcutaneous drug delivery and uses therefor |
US7235164B2 (en) * | 2002-10-18 | 2007-06-26 | Eksigent Technologies, Llc | Electrokinetic pump having capacitive electrodes |
US7517440B2 (en) | 2002-07-17 | 2009-04-14 | Eksigent Technologies Llc | Electrokinetic delivery systems, devices and methods |
WO2004066903A2 (en) * | 2003-01-29 | 2004-08-12 | E-Pill Pharma Ltd. | Active drug delivery in the gastrointestinal tract |
US20040267240A1 (en) * | 2003-01-29 | 2004-12-30 | Yossi Gross | Active drug delivery in the gastrointestinal tract |
US7220597B2 (en) * | 2003-01-30 | 2007-05-22 | Zin Benedict L | Assay test device and method of making same |
US20040158194A1 (en) * | 2003-02-06 | 2004-08-12 | Wolff Andy And Beiski Ben Z. | Oral devices and methods for controlled drug release |
US20040199204A1 (en) * | 2003-02-14 | 2004-10-07 | Voegele James W. | Multifunctional surgical instrument |
US20040225217A1 (en) * | 2003-02-14 | 2004-11-11 | Voegele James W. | Fingertip ultrasound medical instrument |
US20040193211A1 (en) * | 2003-02-14 | 2004-09-30 | Voegele James W. | Fingertip surgical instruments |
US8118722B2 (en) | 2003-03-07 | 2012-02-21 | Neuronetics, Inc. | Reducing discomfort caused by electrical stimulation |
US7153256B2 (en) * | 2003-03-07 | 2006-12-26 | Neuronetics, Inc. | Reducing discomfort caused by electrical stimulation |
WO2004112689A2 (en) * | 2003-06-23 | 2004-12-29 | Transpharma Medical Ltd. | Transdermal delivery system for cosmetic agents |
US20040267283A1 (en) * | 2003-06-25 | 2004-12-30 | Daniela Mavor | Method, device and kit for body decoration |
US7477939B2 (en) * | 2003-06-30 | 2009-01-13 | Johnson & Johnson Consumer Companies, Inc. | Methods of treating a wound with galvanic generated electricity |
US7486989B2 (en) * | 2003-06-30 | 2009-02-03 | Johnson & Johnson Consumer Companies, Inc. | Device for delivery of oxidizing agents to barrier membranes |
US7477938B2 (en) * | 2003-06-30 | 2009-01-13 | Johnson & Johnson Cosumer Companies, Inc. | Device for delivery of active agents to barrier membranes |
US7480530B2 (en) * | 2003-06-30 | 2009-01-20 | Johnson & Johnson Consumer Companies, Inc. | Device for treatment of barrier membranes |
US7476222B2 (en) * | 2003-06-30 | 2009-01-13 | Johnson & Johnson Consumer Companies, Inc. | Methods of reducing the appearance of pigmentation with galvanic generated electricity |
US7477940B2 (en) * | 2003-06-30 | 2009-01-13 | J&J Consumer Companies, Inc. | Methods of administering an active agent to a human barrier membrane with galvanic generated electricity |
US8734421B2 (en) | 2003-06-30 | 2014-05-27 | Johnson & Johnson Consumer Companies, Inc. | Methods of treating pores on the skin with electricity |
US7479133B2 (en) * | 2003-06-30 | 2009-01-20 | Johnson & Johnson Consumer Companies, Inc. | Methods of treating acne and rosacea with galvanic generated electricity |
US7507228B2 (en) * | 2003-06-30 | 2009-03-24 | Johnson & Johnson Consumer Companies, Inc. | Device containing a light emitting diode for treatment of barrier membranes |
US7477941B2 (en) * | 2003-06-30 | 2009-01-13 | Johnson & Johnson Consumer Companies, Inc. | Methods of exfoliating the skin with electricity |
US20040265395A1 (en) * | 2003-06-30 | 2004-12-30 | Ying Sun | Device for delivery of reducing agents to barrier membranes |
EP1648556A1 (en) * | 2003-07-14 | 2006-04-26 | Power Paper Ltd. | Method, apparatus, and kit for onychomycosis treatment using electrokinetic transport of substances |
US8455228B2 (en) * | 2003-07-16 | 2013-06-04 | University Of South Florida | Method to facilitate directed delivery and electroporation using a charged stream |
US8313775B2 (en) | 2003-07-21 | 2012-11-20 | Shionogi Inc. | Antibiotic product, use and formulation thereof |
US8313776B2 (en) * | 2003-07-21 | 2012-11-20 | Shionogi Inc. | Antibiotic product, use and formulation thereof |
JP2006528185A (en) * | 2003-07-21 | 2006-12-14 | アドバンシス ファーマスーティカル コーポレイション | Antibiotic preparations, their use and preparation |
WO2005016311A1 (en) * | 2003-08-11 | 2005-02-24 | Advancis Pharmaceutical Corporation | Robust pellet |
JP2007502294A (en) * | 2003-08-12 | 2007-02-08 | アドバンシス ファーマスーティカル コーポレイション | Antibiotic preparations, their use and preparation |
EP1658034A4 (en) * | 2003-08-29 | 2011-06-22 | Middlebrook Pharmaceuticals Inc | Antibiotic product, use and formulation thereof |
JP2007513869A (en) * | 2003-09-15 | 2007-05-31 | アドバンシス ファーマスーティカル コーポレイション | Antibiotic preparations, their use and preparation |
US20050096550A1 (en) * | 2003-10-31 | 2005-05-05 | Medtronic, Inc. | Techniques for transrectal delivery of a denervating agent to the prostate gland |
US20050096549A1 (en) * | 2003-10-31 | 2005-05-05 | Medtronic, Inc. | Techniques for transperineal delivery of a denervating agent to the prostate gland |
US8048423B2 (en) * | 2003-12-09 | 2011-11-01 | Allergan, Inc. | Botulinum toxin therapy for skin disorders |
US20050148910A1 (en) * | 2003-12-24 | 2005-07-07 | Gregory Skover | Apparatus having a skin-contactable element containing an agent |
WO2005062898A2 (en) * | 2003-12-24 | 2005-07-14 | Advancis Pharmaceutical Corporation | Enhanced absorption of modified release dosage forms |
US8666486B2 (en) | 2004-03-04 | 2014-03-04 | Hadasit Medical Research Services & Development Limited | Safe device for iontophoretic delivery of drugs |
US8936560B2 (en) * | 2004-03-10 | 2015-01-20 | Vision Quest Industries Incorporated | Bracing and electrostimulation for arthritis |
US8454543B2 (en) * | 2004-03-10 | 2013-06-04 | Vision Quest Industries Incorporated | Electrodes for orthotic device |
US20080234225A1 (en) * | 2004-03-15 | 2008-09-25 | John Lezdey | Method of treatment |
US7559356B2 (en) * | 2004-04-19 | 2009-07-14 | Eksident Technologies, Inc. | Electrokinetic pump driven heat transfer system |
US7521140B2 (en) * | 2004-04-19 | 2009-04-21 | Eksigent Technologies, Llc | Fuel cell system with electrokinetic pump |
WO2005115225A2 (en) | 2004-05-27 | 2005-12-08 | Ben Zion Beiski | Intraoral apparatus and method for blood and saliva monitoring & sensing |
US7826726B2 (en) * | 2004-06-07 | 2010-11-02 | Mccoy Mark S | Intra-convertible thermal vapor extraction and delivery system |
JP2008505124A (en) * | 2004-07-02 | 2008-02-21 | アドバンシス ファーマスーティカル コーポレイション | Pulse delivery tablets |
US20070292445A1 (en) * | 2004-07-06 | 2007-12-20 | Transpharma Medical Ltd. | Delivery system for transdermal immunization |
TWI259091B (en) * | 2004-07-09 | 2006-08-01 | Nat Univ Chung Cheng | Electrical energy assisting device for transdermal patch |
US7794415B2 (en) * | 2004-07-13 | 2010-09-14 | S.C. Johnson & Son, Inc. | Surface treatment device |
US20060095001A1 (en) * | 2004-10-29 | 2006-05-04 | Transcutaneous Technologies Inc. | Electrode and iontophoresis device |
US7857746B2 (en) | 2004-10-29 | 2010-12-28 | Nueronetics, Inc. | System and method to reduce discomfort using nerve stimulation |
US20080188837A1 (en) * | 2004-12-14 | 2008-08-07 | Ziv Belsky | Local Delivery of Drugs or Substances Using Electronic Permeability Increase |
US8349352B2 (en) * | 2005-02-04 | 2013-01-08 | Auburn University | Therapeutic contact lenses with anti-fungal delivery |
US8388995B1 (en) | 2006-02-03 | 2013-03-05 | Auburn University | Controlled and extended delivery of hyaluronic acid and comfort molecules via a contact lens platform |
EP1848749B1 (en) * | 2005-02-04 | 2018-10-31 | Auburn University | Contact drug delivery system |
US9238003B2 (en) | 2005-02-04 | 2016-01-19 | Auburn University | Extended or continuous wear silicone hydrogel contact lenses for the extended release of comfort molecules |
US8157807B2 (en) * | 2005-06-02 | 2012-04-17 | The Invention Science Fund I, Llc | Skin treatment including patterned light |
US20060276859A1 (en) * | 2005-06-02 | 2006-12-07 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Photopatterning of skin |
JP4360497B2 (en) * | 2005-03-09 | 2009-11-11 | 国立大学法人 東京大学 | Electric tactile presentation device and electric tactile presentation method |
US20060264804A1 (en) * | 2005-04-07 | 2006-11-23 | Yoram Karmon | Device and kit for delivery of encapsulated substances and methods of use thereof |
US20060229524A1 (en) * | 2005-04-08 | 2006-10-12 | Alden Ozment | Method for the accurate placement of EKG electrodes |
US7856263B2 (en) * | 2005-04-22 | 2010-12-21 | Travanti Pharma Inc. | Transdermal systems for the delivery of therapeutic agents including granisetron using iontophoresis |
US7300409B2 (en) * | 2005-05-12 | 2007-11-27 | S.C. Johnson & Son, Inc. | Therapy patch |
CN101175529A (en) * | 2005-05-19 | 2008-05-07 | 埃-皮尔制药公司 | Ingestible device for nitric oxide production in tissue |
US20070106138A1 (en) * | 2005-05-26 | 2007-05-10 | Beiski Ben Z | Intraoral apparatus for non-invasive blood and saliva monitoring & sensing |
US20070032846A1 (en) * | 2005-08-05 | 2007-02-08 | Bran Ferren | Holographic tattoo |
JP2006346368A (en) * | 2005-06-20 | 2006-12-28 | Transcutaneous Technologies Inc | Iontophoresis apparatus and manufacturing method |
US20070045337A1 (en) * | 2005-06-24 | 2007-03-01 | Hornsby James R | Dispensing device |
US20070016277A1 (en) * | 2005-07-05 | 2007-01-18 | Carol Karat | Lip augmentation device |
US20070009542A1 (en) * | 2005-07-05 | 2007-01-11 | Galit Levin | Method and device for transdermal immunization |
US20070038270A1 (en) * | 2005-07-05 | 2007-02-15 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Multi step photopatterning of skin |
US20090214625A1 (en) * | 2005-07-15 | 2009-08-27 | Mizuo Nakayama | Drug delivery patch |
US7824324B2 (en) | 2005-07-27 | 2010-11-02 | Neuronetics, Inc. | Magnetic core for medical procedures |
US7793666B2 (en) * | 2005-07-28 | 2010-09-14 | Innovation Biomedical Devices, Inc. | Apparatus and method for treatment of infected nail |
JP2007037868A (en) * | 2005-08-05 | 2007-02-15 | Transcutaneous Technologies Inc | Transdermal administration device and its controlling method |
US8386030B2 (en) | 2005-08-08 | 2013-02-26 | Tti Ellebeau, Inc. | Iontophoresis device |
US8295922B2 (en) | 2005-08-08 | 2012-10-23 | Tti Ellebeau, Inc. | Iontophoresis device |
CA2985955C (en) | 2005-08-12 | 2020-07-07 | Tcms Transparent Beauty Llc | System and method for medical monitoring and treatment through cosmetic monitoring and treatment |
US20070060860A1 (en) * | 2005-08-18 | 2007-03-15 | Transcutaneous Technologies Inc. | Iontophoresis device |
US20100016781A1 (en) * | 2005-08-29 | 2010-01-21 | Mizuo Nakayama | Iontophoresis device selecting drug to be administered on the basis of information form sensor |
US20070048340A1 (en) * | 2005-08-31 | 2007-03-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Multi step patterning of a skin surface |
WO2007029611A1 (en) * | 2005-09-06 | 2007-03-15 | Tti Ellebeau, Inc. | Iontophoresis device |
JPWO2007032446A1 (en) | 2005-09-15 | 2009-03-19 | Tti・エルビュー株式会社 | Rod iontophoresis device |
NZ566628A (en) * | 2005-09-16 | 2010-02-26 | Tti Ellebeau Inc | Catheter type iontophoresis apparatus using alternating layers of electrolytes and ion exchange membranes |
US20070066934A1 (en) * | 2005-09-19 | 2007-03-22 | Transport Pharmaceuticals, Inc. | Electrokinetic delivery system and methods therefor |
US20070185432A1 (en) * | 2005-09-19 | 2007-08-09 | Transport Pharmaceuticals, Inc. | Electrokinetic system and method for delivering methotrexate |
EP1937226A2 (en) * | 2005-09-23 | 2008-07-02 | Alza Corporation | Transdermal galantamine delivery system |
US20070071807A1 (en) * | 2005-09-28 | 2007-03-29 | Hidero Akiyama | Capsule-type drug-releasing device and capsule-type drug-releasing device system |
WO2007037324A1 (en) * | 2005-09-28 | 2007-04-05 | Transcu Ltd. | Dry electrode construct for iontophoresis |
US20070078445A1 (en) * | 2005-09-30 | 2007-04-05 | Curt Malloy | Synchronization apparatus and method for iontophoresis device to deliver active agents to biological interfaces |
JP2009509691A (en) * | 2005-09-30 | 2009-03-12 | Tti・エルビュー株式会社 | An iontophoresis device for delivering multiple active substances to a biological interface |
US20090299265A1 (en) * | 2005-09-30 | 2009-12-03 | Tti Ellebeau, Inc. | Electrode Assembly for Iontophoresis Having Shape-Memory Separator and Iontophoresis Device Using the Same |
US20070232983A1 (en) * | 2005-09-30 | 2007-10-04 | Smith Gregory A | Handheld apparatus to deliver active agents to biological interfaces |
WO2007037476A1 (en) * | 2005-09-30 | 2007-04-05 | Tti Ellebeau, Inc. | Iontophoresis apparatus capable of controlling dose and timing of administration of sleep inducer and analeptic agent |
US20070197955A1 (en) * | 2005-10-12 | 2007-08-23 | Transcutaneous Technologies Inc. | Mucous membrane adhesion-type iontophoresis device |
EP1957794B1 (en) | 2005-11-23 | 2014-07-02 | Eksigent Technologies, LLC | Electrokinetic pump designs and drug delivery systems |
US8099162B2 (en) * | 2005-11-29 | 2012-01-17 | Eyegate Pharma, S.A.S. | Ocular iontophoresis device |
FR2893852B1 (en) * | 2005-11-29 | 2010-09-03 | Eyegate Pharma Sa | OCULAR IONTOPHORESIS DEVICE |
AU2006320594A1 (en) * | 2005-11-30 | 2007-06-07 | Transport Pharmaceuticals, Inc. | An applicator cartridge for an electrokinetic delivery system for self administration of medicaments |
CA2624152A1 (en) * | 2005-11-30 | 2007-06-07 | Transport Pharmaceuticals, Inc. | Combination cartridge and device for electrokinetic delivery of medicament to a treatment site |
US8357394B2 (en) | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
US8778924B2 (en) | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
JP4804904B2 (en) * | 2005-12-09 | 2011-11-02 | Tti・エルビュー株式会社 | Iontophoresis device packaging |
WO2007079116A1 (en) * | 2005-12-28 | 2007-07-12 | Tti Ellebeau, Inc. | Electroosmotic pump apparatus and method to deliver active agents to biological interfaces |
WO2007079190A2 (en) * | 2005-12-29 | 2007-07-12 | Tti Ellebeau, Inc. | Device and method for enhancing immune response by electrical stimulation |
US8048089B2 (en) | 2005-12-30 | 2011-11-01 | Edge Systems Corporation | Apparatus and methods for treating the skin |
JP2009522011A (en) | 2005-12-30 | 2009-06-11 | Tti・エルビュー株式会社 | Iontophoresis system, apparatus and method for delivering an active substance to a biological interface |
WO2007098058A2 (en) * | 2006-02-16 | 2007-08-30 | Biodel, Inc. | Device for sublingual drug delivery using iontophoresis |
US8036738B2 (en) * | 2006-03-14 | 2011-10-11 | New Jersey Institute Of Technology | Iontophoretic transdermal drug delivery system based on conductive polyaniline membrane |
US20070225585A1 (en) * | 2006-03-22 | 2007-09-27 | Washbon Lori A | Headset for electrodes |
US10172644B2 (en) | 2006-03-29 | 2019-01-08 | Edge Systems Llc | Devices, systems and methods for treating the skin |
WO2014151104A1 (en) | 2013-03-15 | 2014-09-25 | Edge Systems Llc | Devices, systems and methods for treating the skin |
US9566088B2 (en) | 2006-03-29 | 2017-02-14 | Edge Systems Llc | Devices, systems and methods for treating the skin |
WO2007123707A1 (en) * | 2006-03-30 | 2007-11-01 | Tti Ellebeau, Inc. | Controlled release membrane and methods of use |
US8158109B2 (en) | 2006-03-31 | 2012-04-17 | Stiefel Research Australia Pty Ltd | Foamable suspension gel |
FR2899487A1 (en) * | 2006-04-10 | 2007-10-12 | Galderma Res & Dev | APPLICATION OF ULTRASOUNDS TO NAILS |
CN101466329A (en) * | 2006-04-20 | 2009-06-24 | 坦瑞斯波特医药品公司 | Pharmaceutical formulations for iontophoretic drug delivery |
WO2007124372A2 (en) * | 2006-04-20 | 2007-11-01 | Transport Pharmaceuticals, Inc. | Pharmaceutical formulations for iontophoretic methotrexate delivery |
US8299052B2 (en) | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
US20070276318A1 (en) * | 2006-05-26 | 2007-11-29 | Mit, Llp | Iontosonic-microneedle applicator apparatus and methods |
US20070282246A1 (en) * | 2006-06-05 | 2007-12-06 | Mit, Llp | Iontosonic-microneedle biosensor apparatus and methods |
EP2040794A4 (en) * | 2006-06-16 | 2010-10-20 | Transport Pharmaceuticals Inc | Pharmaceutical formulations for iontophoretic tetracycline antibiotic delivery |
KR20090027755A (en) * | 2006-07-05 | 2009-03-17 | 티티아이 엘뷰 가부시키가이샤 | Delivery device having self-assembling dendritic polymers and method of use thereof |
US8184901B2 (en) | 2007-02-12 | 2012-05-22 | Tcms Transparent Beauty Llc | System and method for applying a reflectance modifying agent to change a person's appearance based on a digital image |
US20080077076A1 (en) * | 2006-08-29 | 2008-03-27 | Transcutaneous Technologies Inc. | Iontophoresis device and method for operation with a usb (universal serial bus) power source |
JP2010502263A (en) * | 2006-08-30 | 2010-01-28 | エルジー ハウスホールド アンド ヘルス ケア エルティーディー. | Iontophoresis device |
WO2008030497A2 (en) * | 2006-09-05 | 2008-03-13 | Tti Ellebeau, Inc. | Transdermal drug delivery systems, devices, and methods using inductive power supplies |
AU2007308838B2 (en) | 2006-10-25 | 2014-03-13 | Revalesio Corporation | Mixing device and output fluids of same |
US8784898B2 (en) | 2006-10-25 | 2014-07-22 | Revalesio Corporation | Methods of wound care and treatment |
AU2007308840C1 (en) | 2006-10-25 | 2014-09-25 | Revalesio Corporation | Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution |
US8609148B2 (en) | 2006-10-25 | 2013-12-17 | Revalesio Corporation | Methods of therapeutic treatment of eyes |
US8784897B2 (en) | 2006-10-25 | 2014-07-22 | Revalesio Corporation | Methods of therapeutic treatment of eyes |
CA2667614A1 (en) | 2006-10-25 | 2008-09-25 | Revalesio Corporation | Method of wound care and treatment |
US8445546B2 (en) | 2006-10-25 | 2013-05-21 | Revalesio Corporation | Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures |
US20080193514A1 (en) * | 2006-11-02 | 2008-08-14 | Transcu Ltd. | Compostions and methods for iontophoresis delivery of active ingredients through hair follicles |
US20080138408A1 (en) | 2006-11-13 | 2008-06-12 | Siddharth Venkatesh | Drug delivery system and method |
US20100076367A1 (en) * | 2006-11-24 | 2010-03-25 | Koninklijke Philips Electronics N. V. | Iontophoretic device |
US8062783B2 (en) | 2006-12-01 | 2011-11-22 | Tti Ellebeau, Inc. | Systems, devices, and methods for powering and/or controlling devices, for instance transdermal delivery devices |
WO2008087803A1 (en) * | 2007-01-16 | 2008-07-24 | Hokkaido University | Liposome preparation for iontophoresis having antioxidant component encapsulated therein |
US7867592B2 (en) | 2007-01-30 | 2011-01-11 | Eksigent Technologies, Inc. | Methods, compositions and devices, including electroosmotic pumps, comprising coated porous surfaces |
CN101641161B (en) | 2007-02-12 | 2012-04-18 | Tcms剔透美丽有限责任公司 | System and method for applying agent electrostatically to human skin |
US8075482B2 (en) * | 2007-02-22 | 2011-12-13 | Ethicon Endo-Surgery, Inc. | IRIS valve with control ring |
US8070770B2 (en) * | 2007-02-22 | 2011-12-06 | Ethicon Endo-Surgery, Inc. | Iris valve with novel locking mechanism |
WO2008109694A1 (en) * | 2007-03-06 | 2008-09-12 | Emotiv Systems Pty Ltd | Electrode and electrode headset |
WO2008121709A1 (en) * | 2007-03-30 | 2008-10-09 | Transport Pharmaceuticals, Inc. | Pharmaceutical formulations for iontophoretic delivery of an anti-fungal drug |
US20080262581A1 (en) * | 2007-04-17 | 2008-10-23 | Transport Pharmaceuticals, Inc. | Current density detection and control system and method for an electrokinetic delivery of medicaments |
WO2008131205A1 (en) * | 2007-04-20 | 2008-10-30 | Transport Pharmaceuticals, Inc. | A single use applicator cartridge for an electrokinetic delivery system and method for self administration of medicaments |
US10092082B2 (en) | 2007-05-29 | 2018-10-09 | Tcms Transparent Beauty Llc | Apparatus and method for the precision application of cosmetics |
US8197844B2 (en) | 2007-06-08 | 2012-06-12 | Activatek, Inc. | Active electrode for transdermal medicament administration |
JP2010187707A (en) * | 2007-06-12 | 2010-09-02 | Hokkaido Univ | Liposome preparation for iontophoresis comprising insulin encapsulated therein |
US20080312580A1 (en) * | 2007-06-15 | 2008-12-18 | Transport Pharmaceuticals, Inc. | Current concentration system and method for electrokinetic delivery of medicaments |
JP2010529897A (en) * | 2007-06-15 | 2010-09-02 | ニトリツク・バイオ・セラピユーテイクス・インコーポレーテツド | Current concentration mitigation method and system for electrokinetic drug delivery |
US8845630B2 (en) | 2007-06-15 | 2014-09-30 | Syneron Medical Ltd | Devices and methods for percutaneous energy delivery |
US20120143178A9 (en) * | 2007-06-15 | 2012-06-07 | Primaeva Medical, Inc. | Devices and methods for percutaneous energy delivery |
US20080319371A1 (en) * | 2007-06-19 | 2008-12-25 | Transport Pharmaceuticals, Inc. | Method and system for treating of onychomycosis with an applicator having a gel medicament layer |
US8560088B2 (en) * | 2007-07-30 | 2013-10-15 | Citieffe S.R.L. | Medical device, in particular for electroporation treatment |
EP2200666B1 (en) * | 2007-10-09 | 2014-12-03 | Syneron Medical Ltd. | Magnetic patch coupling |
US9523090B2 (en) | 2007-10-25 | 2016-12-20 | Revalesio Corporation | Compositions and methods for treating inflammation |
CA2703648A1 (en) * | 2007-10-25 | 2009-04-30 | Revalesio Corporation | Bacteriostatic or bacteriocidal compositions and methods |
US9745567B2 (en) | 2008-04-28 | 2017-08-29 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
US10125359B2 (en) | 2007-10-25 | 2018-11-13 | Revalesio Corporation | Compositions and methods for treating inflammation |
AU2008332738B2 (en) | 2007-12-05 | 2013-08-15 | Syneron Medical Ltd. | A disposable electromagnetic energy applicator and method of using it |
WO2009076134A1 (en) | 2007-12-11 | 2009-06-18 | Eksigent Technologies, Llc | Electrokinetic pump with fixed stroke volume |
EP2240099B1 (en) | 2008-01-04 | 2018-02-21 | Edge Systems LLC | Apparatus for treating the skin |
CN101938951B (en) | 2008-01-17 | 2013-06-12 | 赛诺龙医疗公司 | A hair removal apparatus for personal use and the method of using same |
US8862223B2 (en) | 2008-01-18 | 2014-10-14 | Activatek, Inc. | Active transdermal medicament patch and circuit board for same |
WO2009093230A2 (en) | 2008-01-24 | 2009-07-30 | Syneron Medical Ltd. | A device, apparatus, and method of adipose tissue treatment |
US9056193B2 (en) | 2008-01-29 | 2015-06-16 | Edge Systems Llc | Apparatus and method for treating the skin |
EP2285347A4 (en) | 2008-05-01 | 2011-09-21 | Revalesio Corp | Compositions and methods for treating digestive disorders |
US20100021530A1 (en) * | 2008-07-25 | 2010-01-28 | Innovation Biomedical Devices, Inc. | Enhanced trans-keratin drug delivery |
US8150525B2 (en) * | 2008-08-27 | 2012-04-03 | Johnson & Johnson Consumer Companies, Inc. | Treatment of hyperhydrosis |
RU2375955C1 (en) * | 2008-09-04 | 2009-12-20 | ООО "Исследовательско-технологический центр "Аусферр" | Device for determining acupuncture points parametres |
AR073575A1 (en) * | 2008-09-10 | 2010-11-17 | Transcu Ltd | APPARATUS AND METHOD FOR DISPENSING HPC-BASED VISCOSE LIQUIDS IN POROUS SUBSTRATES FOR EXAMPLE CONTINUOUS BAND-BASED PROCESS |
MX2011002987A (en) | 2008-09-21 | 2011-07-20 | Syneron Medical Ltd | A method and apparatus for personal skin treatment. |
US9566256B2 (en) | 2008-09-22 | 2017-02-14 | Biochemics, Inc. | Transdermal drug delivery using an osmolyte and vasoactive agent |
US9675443B2 (en) | 2009-09-10 | 2017-06-13 | Johnson & Johnson Vision Care, Inc. | Energized ophthalmic lens including stacked integrated components |
EP2365812A4 (en) | 2008-11-10 | 2012-05-16 | Nitric Biotherapeutics Inc | Pharmaceutical formulations for iontophoretic delivery of a corticosteroid |
EP2352543B1 (en) | 2008-12-04 | 2019-04-03 | BioChemics, Inc. | Methods and compositions for tattoo removal |
US8606366B2 (en) | 2009-02-18 | 2013-12-10 | Syneron Medical Ltd. | Skin treatment apparatus for personal use and method for using same |
KR20120090007A (en) * | 2009-02-25 | 2012-08-16 | 프리마바 메디컬, 아이엔씨. | Devices and methods for percutaneous energy delivery |
US20120089232A1 (en) | 2009-03-27 | 2012-04-12 | Jennifer Hagyoung Kang Choi | Medical devices with galvanic particulates |
WO2010118153A1 (en) * | 2009-04-07 | 2010-10-14 | Nitric Biotherapeutics, Inc. | Controlling drug transport and current in iontophoretic onychomycosis treatment |
US8815292B2 (en) | 2009-04-27 | 2014-08-26 | Revalesio Corporation | Compositions and methods for treating insulin resistance and diabetes mellitus |
US20100286587A1 (en) * | 2009-05-07 | 2010-11-11 | Yossi Gross | Sublingual electrical drug delivery |
US8414559B2 (en) | 2009-05-07 | 2013-04-09 | Rainbow Medical Ltd. | Gastroretentive duodenal pill |
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
US20100312168A1 (en) * | 2009-06-09 | 2010-12-09 | Yoshimasa Yoshida | Long life high capacity electrode, device, and method of manufacture |
WO2011002776A1 (en) * | 2009-06-29 | 2011-01-06 | Nitric Biotherapeutics, Inc. | Pharmaceutical formulations for iontophoretic delivery of an immunomodulator |
EP2451367B1 (en) | 2009-07-08 | 2020-01-22 | Edge Systems Corporation | Devices for treating the skin using time-release substances |
US9415203B2 (en) * | 2009-08-28 | 2016-08-16 | Caci Microlift Limited | Electrostimulation devices |
US9937343B2 (en) | 2009-08-28 | 2018-04-10 | Caci Microlift Limited | Electrostimulation skin massage devices |
US9014799B2 (en) * | 2009-10-08 | 2015-04-21 | Palo Alto Research Center Incorporated | Transmucosal drug delivery device and method including electrically-actuated permeation enhancement |
US8882748B2 (en) * | 2009-10-08 | 2014-11-11 | Palo Alto Research Center Incorporated | Transmucosal drug delivery device and method including chemical permeation enhancers |
US9017310B2 (en) * | 2009-10-08 | 2015-04-28 | Palo Alto Research Center Incorporated | Transmucosal drug delivery device and method including microneedles |
US8744567B2 (en) * | 2009-11-13 | 2014-06-03 | Johnson & Johnson Consumer Companies, Inc. | Galvanic skin treatment device |
JP5463136B2 (en) * | 2009-12-22 | 2014-04-09 | 帝國製薬株式会社 | Electrode device used for iontophoresis therapy |
ES2928669T3 (en) | 2009-12-31 | 2022-11-22 | Zetroz Systems Llc | Ultrasound Docking Device |
CN103079634B (en) * | 2010-03-17 | 2016-01-20 | 苏州纳通生物纳米技术有限公司 | The built-in non-language coaching device of giver can be integrated into |
CN101837163B (en) * | 2010-04-12 | 2013-04-10 | 上海现代药物制剂工程研究中心有限公司 | Heparin rectum iontophoretic drug delivery system |
US9237961B2 (en) * | 2010-04-23 | 2016-01-19 | Medtronic Vascular, Inc. | Stent delivery system for detecting wall apposition of the stent during deployment |
BR112012028540A2 (en) | 2010-05-07 | 2016-07-26 | Revalesio Corp | compositions and methods for improving physiological performance and recovery time |
AU2011289172B2 (en) | 2010-08-12 | 2015-09-24 | Revalesio Corporation | Compositions and methods for treatment of taupathy |
TWI394587B (en) * | 2011-01-07 | 2013-05-01 | Iner Aec Executive Yuan | A radiolabeled nucleoside analogue, a method for preparing the same and the use thereof |
AU2011200394B2 (en) * | 2011-01-31 | 2015-01-22 | Palo Alto Research Center Incorporated | Transmucosal drug delivery device and method including electrically-actuated permeation enhancement |
US8950862B2 (en) | 2011-02-28 | 2015-02-10 | Johnson & Johnson Vision Care, Inc. | Methods and apparatus for an ophthalmic lens with functional insert layers |
US8970559B1 (en) * | 2011-03-08 | 2015-03-03 | Henry Lansing McVickar | Fingernail stylus |
US9889615B2 (en) | 2011-03-18 | 2018-02-13 | Johnson & Johnson Vision Care, Inc. | Stacked integrated component media insert for an ophthalmic device |
US9698129B2 (en) | 2011-03-18 | 2017-07-04 | Johnson & Johnson Vision Care, Inc. | Stacked integrated component devices with energization |
US9110310B2 (en) | 2011-03-18 | 2015-08-18 | Johnson & Johnson Vision Care, Inc. | Multiple energization elements in stacked integrated component devices |
US10451897B2 (en) | 2011-03-18 | 2019-10-22 | Johnson & Johnson Vision Care, Inc. | Components with multiple energization elements for biomedical devices |
US9804418B2 (en) * | 2011-03-21 | 2017-10-31 | Johnson & Johnson Vision Care, Inc. | Methods and apparatus for functional insert with power layer |
EP2704759A4 (en) | 2011-05-05 | 2015-06-03 | Eksigent Technologies Llc | Gel coupling for electrokinetic delivery systems |
US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
US10004526B2 (en) * | 2011-07-25 | 2018-06-26 | Covidien Lp | Ultrasonic dissection system |
US9327119B2 (en) | 2011-07-27 | 2016-05-03 | Vision Quest Industries Incorporated | Electrostimulation system |
JP6594625B2 (en) * | 2011-09-09 | 2019-10-23 | インターナショナル・サイエンティフィック・プロプライエタリー・リミテッド | Methods and devices for transdermal delivery of substances |
US8857983B2 (en) | 2012-01-26 | 2014-10-14 | Johnson & Johnson Vision Care, Inc. | Ophthalmic lens assembly having an integrated antenna structure |
US9980810B2 (en) * | 2012-04-03 | 2018-05-29 | Johnson & Johnson Vision Care, Inc. | System controller for variable-optic electronic ophthalmic lens |
US9351827B2 (en) * | 2012-04-03 | 2016-05-31 | Johnson & Johnson Vision Care, Inc. | Lens driver for variable-optic electronic ophthalmic lens |
RU2495628C1 (en) * | 2012-04-18 | 2013-10-20 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) | Method of selecting tactics of treating actinic keratosis |
WO2013190537A1 (en) * | 2012-06-18 | 2013-12-27 | Michael Tavger | Method and system for delivering solution into the pores of recipient human skin |
US9271783B2 (en) | 2012-07-17 | 2016-03-01 | Covidien Lp | End-effector assembly including a pressure-sensitive layer disposed on an electrode |
US20140088372A1 (en) * | 2012-09-25 | 2014-03-27 | Google Inc. | Information processing method |
US9999720B2 (en) | 2012-09-27 | 2018-06-19 | Palo Alto Research Center Incorporated | Drug reconstitution and delivery device and methods |
US9005108B2 (en) | 2012-09-27 | 2015-04-14 | Palo Alto Research Center Incorporated | Multiple reservoir drug delivery device and methods |
US9872812B2 (en) | 2012-09-28 | 2018-01-23 | Kpr U.S., Llc | Residual pressure control in a compression device |
US9744341B2 (en) | 2013-01-15 | 2017-08-29 | Palo Alto Research Center Incorporated | Devices and methods for intraluminal retention and drug delivery |
US9050053B2 (en) | 2013-02-15 | 2015-06-09 | Naimco, Inc. | Ultrasound device with cavity for conductive medium |
US10238812B2 (en) | 2013-03-15 | 2019-03-26 | Edge Systems Llc | Skin treatment systems and methods using needles |
US9592151B2 (en) | 2013-03-15 | 2017-03-14 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
US9320645B2 (en) * | 2013-05-29 | 2016-04-26 | Terry Glasser | Approach to administering ocular medication |
PL3003473T3 (en) * | 2013-05-30 | 2019-05-31 | Neurostim Solutions LLC | Topical neurological stimulation |
US9549703B2 (en) | 2013-11-27 | 2017-01-24 | Elwha Llc | Devices and methods for sampling and profiling microbiota of skin |
US9526480B2 (en) | 2013-11-27 | 2016-12-27 | Elwha Llc | Devices and methods for profiling microbiota of skin |
US9390312B2 (en) | 2013-08-23 | 2016-07-12 | Elwha Llc | Systems, methods, and devices for assessing microbiota of skin |
US9456777B2 (en) | 2013-08-23 | 2016-10-04 | Elwha Llc | Systems, methods, and devices for assessing microbiota of skin |
US9557331B2 (en) | 2013-08-23 | 2017-01-31 | Elwha Llc | Systems, methods, and devices for assessing microbiota of skin |
US9811641B2 (en) | 2013-08-23 | 2017-11-07 | Elwha Llc | Modifying a cosmetic product based on a microbe profile |
EP3035994B1 (en) * | 2013-08-23 | 2019-04-17 | Elwha LLC | Systems, methods, and devices for delivering treatment to a skin surface |
US10010704B2 (en) | 2013-08-23 | 2018-07-03 | Elwha Llc | Systems, methods, and devices for delivering treatment to a skin surface |
US10152529B2 (en) | 2013-08-23 | 2018-12-11 | Elwha Llc | Systems and methods for generating a treatment map |
US9805171B2 (en) | 2013-08-23 | 2017-10-31 | Elwha Llc | Modifying a cosmetic product based on a microbe profile |
WO2015052705A1 (en) * | 2013-10-09 | 2015-04-16 | Venus Concept Ltd | Integrated treatment system |
JP6538063B2 (en) * | 2013-11-05 | 2019-07-03 | シンアジャル コーポレイション | Device and method for continuous drug delivery through the mouth |
US9610037B2 (en) | 2013-11-27 | 2017-04-04 | Elwha Llc | Systems and devices for profiling microbiota of skin |
US9526450B2 (en) | 2013-11-27 | 2016-12-27 | Elwha Llc | Devices and methods for profiling microbiota of skin |
US9186278B2 (en) | 2013-11-27 | 2015-11-17 | Elwha Llc | Systems and devices for sampling and profiling microbiota of skin |
US9297083B2 (en) | 2013-12-16 | 2016-03-29 | Palo Alto Research Center Incorporated | Electrolytic gas generating devices, actuators, and methods |
US20150265825A1 (en) | 2014-03-21 | 2015-09-24 | L'oreal | Combined sonic and iontophoretic skin care device |
JP6655610B2 (en) | 2014-05-29 | 2020-02-26 | グローコス コーポレーション | IMPLANT WITH CONTROLLED DRUG DELIVERY FUNCTION AND METHOD OF USING THE SAME |
JP6444069B2 (en) * | 2014-06-17 | 2018-12-26 | マクセルホールディングス株式会社 | Skin care equipment |
US9801660B2 (en) | 2014-07-31 | 2017-10-31 | Palo Alto Research Center Incorporated | Implantable fluid delivery devices, systems, and methods |
US10278675B2 (en) | 2014-07-31 | 2019-05-07 | Palo Alto Research Center Incorporated | Implantable estrus detection devices, systems, and methods |
US10361405B2 (en) | 2014-08-21 | 2019-07-23 | Johnson & Johnson Vision Care, Inc. | Biomedical energization elements with polymer electrolytes |
US9715130B2 (en) | 2014-08-21 | 2017-07-25 | Johnson & Johnson Vision Care, Inc. | Methods and apparatus to form separators for biocompatible energization elements for biomedical devices |
US9599842B2 (en) | 2014-08-21 | 2017-03-21 | Johnson & Johnson Vision Care, Inc. | Device and methods for sealing and encapsulation for biocompatible energization elements |
US10361404B2 (en) | 2014-08-21 | 2019-07-23 | Johnson & Johnson Vision Care, Inc. | Anodes for use in biocompatible energization elements |
US9383593B2 (en) | 2014-08-21 | 2016-07-05 | Johnson & Johnson Vision Care, Inc. | Methods to form biocompatible energization elements for biomedical devices comprising laminates and placed separators |
US9941547B2 (en) | 2014-08-21 | 2018-04-10 | Johnson & Johnson Vision Care, Inc. | Biomedical energization elements with polymer electrolytes and cavity structures |
US9793536B2 (en) | 2014-08-21 | 2017-10-17 | Johnson & Johnson Vision Care, Inc. | Pellet form cathode for use in a biocompatible battery |
US10381687B2 (en) | 2014-08-21 | 2019-08-13 | Johnson & Johnson Vision Care, Inc. | Methods of forming biocompatible rechargable energization elements for biomedical devices |
US10627651B2 (en) | 2014-08-21 | 2020-04-21 | Johnson & Johnson Vision Care, Inc. | Methods and apparatus to form biocompatible energization primary elements for biomedical devices with electroless sealing layers |
KR102472312B1 (en) | 2014-10-21 | 2022-11-29 | 헥시마 리미티드 | A method of treatment |
EP4324414A3 (en) | 2014-12-23 | 2024-05-01 | HydraFacial LLC | Devices and methods for treating the skin using a rollerball or a wicking member |
US10179229B2 (en) | 2014-12-23 | 2019-01-15 | Edge Systems Llc | Devices and methods for treating the skin using a porous member |
US9861818B2 (en) * | 2014-12-31 | 2018-01-09 | Ziip, Llc | Method and device for electrical current treatment |
US11969594B2 (en) | 2014-12-31 | 2024-04-30 | Ziip, Inc. | Electrical current stimulator apparatus |
AU2016258179B2 (en) | 2015-05-06 | 2021-07-01 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
EP3319573A4 (en) | 2015-07-08 | 2019-01-23 | Edge Systems LLC | Devices, systems and methods for promoting hair growth |
US10130578B2 (en) * | 2015-07-23 | 2018-11-20 | Johnson & Johnson Consumer Inc. | Topical delivery of skin compositions having low pH |
WO2017040853A1 (en) | 2015-09-02 | 2017-03-09 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
RU2696028C1 (en) * | 2015-11-13 | 2019-07-30 | Эссити Хайджин Энд Актиеболаг | Wearable absorbent hygienic article containing an electronic unit |
BR112018008317B1 (en) * | 2015-11-13 | 2021-11-09 | Sca Hygiene Products Ab | ABSORBENT HYGIENE ARTICLE USABLE WITH THE BODY, SYSTEM AND METHOD TO USE A HYGIENE ABSORBENT ARTICLE |
US10345620B2 (en) | 2016-02-18 | 2019-07-09 | Johnson & Johnson Vision Care, Inc. | Methods and apparatus to form biocompatible energization elements incorporating fuel cells for biomedical devices |
WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
JP7003110B2 (en) | 2016-04-20 | 2022-01-20 | ドーズ メディカル コーポレーション | Bioabsorbable eye drug delivery device |
AU2017306078B2 (en) * | 2016-08-01 | 2023-03-09 | Drexel University | Devices and methods for treatment of skin conditions |
JP2018042886A (en) * | 2016-09-16 | 2018-03-22 | ロレアル | Portable iontophoresis device |
US10966649B2 (en) * | 2017-03-16 | 2021-04-06 | Fukuda Denshi Co., Ltd. | Bioelectrode sheet |
US10406358B1 (en) * | 2017-04-24 | 2019-09-10 | Todd M. Bertoch | Chronic pain treatment device |
US20200061357A1 (en) * | 2017-05-02 | 2020-02-27 | Georgia Tech Research Corporation | Targeted drug delivery methods using a microneedle |
CN107233084B (en) * | 2017-07-12 | 2024-03-12 | 上海坤浩信息科技有限公司 | Spring vibrator type pulse condition reproduction instrument |
DE102017123809A1 (en) * | 2017-10-12 | 2019-04-18 | Swiss Spa System Ltd. | In one hand durable device for electrically assisted skin treatment, additional part for this device and blister for this additional part |
RU2709159C1 (en) * | 2018-10-26 | 2019-12-16 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Владимирский Государственный Университет имени Александра Григорьевича и Николая Григорьевича Столетовых" (ВлГУ) | Device for treating fungal infections of nails |
USD1016615S1 (en) | 2021-09-10 | 2024-03-05 | Hydrafacial Llc | Container for a skin treatment device |
CN116271113B (en) * | 2023-05-24 | 2023-08-08 | 四川大学华西医院 | Multifunctional photo-curing sound guide gel and preparation method and application thereof |
CN117462836B (en) * | 2023-12-26 | 2024-04-26 | 山东百多安医疗器械股份有限公司 | Functionalized ultrasonic controlled-release puncture dressing patch and preparation method thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5160316A (en) | 1990-09-10 | 1992-11-03 | Henley Julian L | Iontophoretic drug delivery apparatus |
US5310404A (en) * | 1992-06-01 | 1994-05-10 | Alza Corporation | Iontophoretic delivery device and method of hydrating same |
US5562607A (en) * | 1995-01-18 | 1996-10-08 | Alza Corporation | Electrotransport device having reusable controller power saver |
US5908401A (en) * | 1996-05-08 | 1999-06-01 | The Aps Organization, Llp | Method for iontophoretic delivery of antiviral agents |
Family Cites Families (183)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US279524A (en) | 1883-06-19 | Thimble | ||
US206474A (en) | 1878-07-30 | Improvement in glove-electrodes | ||
US484522A (en) | 1892-10-18 | Edward h | ||
US600290A (en) | 1898-03-08 | Therapeutic electrode | ||
DE603705C (en) | 1931-06-18 | 1934-10-08 | Desider Deutsch Dr | Electrode for introducing medicines into the body by means of iontophoresis |
US2126070A (en) | 1932-04-29 | 1938-08-09 | Wappler Frederick Charles | Electrotherapy |
US2047308A (en) | 1934-05-05 | 1936-07-14 | T M Chapman S Sons Co | Electrical therapeutic pad |
US2123980A (en) | 1934-07-21 | 1938-07-19 | G M Basford Company | Therapeutic treatment |
US2834344A (en) | 1954-07-22 | 1958-05-13 | Lion Brush K K | Device for penetrating teeth with fluoride |
US3107672A (en) | 1958-05-27 | 1963-10-22 | Ewald Rose | Electrical apparatus for cosmetic treatment of the skin |
US3019787A (en) | 1960-10-05 | 1962-02-06 | Joe J Simmons | Apparatus for electrolytic dental desensitization |
US3048170A (en) | 1960-11-08 | 1962-08-07 | Lemos Albano | Electrical devices for the application of fluid to the gums |
US3163166A (en) | 1961-04-28 | 1964-12-29 | Colgate Palmolive Co | Iontophoresis apparatus |
US3298368A (en) | 1964-04-24 | 1967-01-17 | Charos Peter | Heated cream applicator gloves |
FR1445703A (en) | 1965-06-03 | 1966-07-15 | Advanced ionization apparatus | |
US3520297A (en) | 1967-01-31 | 1970-07-14 | Chemway Corp | Iontophoretic toothbrush |
US3556105A (en) | 1968-05-24 | 1971-01-19 | Lillian B Shepard | Electrical stimulator and mitten |
US3645260A (en) | 1970-07-17 | 1972-02-29 | Health Systems Inc | Dental desensitizer |
US3716054A (en) | 1970-08-11 | 1973-02-13 | W Porter | Apparatus for applying medication to teeth and body tissue |
US3848600A (en) | 1972-02-03 | 1974-11-19 | Ndm Corp | Indifferent electrode in electrosurgical procedures and method of use |
US3831598A (en) | 1972-09-28 | 1974-08-27 | I Tice | Sterile anesthetic instruments |
US4116238A (en) | 1976-08-18 | 1978-09-26 | Midgard Electronics Company, Inc. | High voltage constant current source for iontophoresis |
US4211222A (en) | 1976-08-25 | 1980-07-08 | Robert Tapper | Iontophoretic burn-protection method |
SU654254A2 (en) | 1977-02-07 | 1979-03-30 | В. Н. Серов | Device for treating eyes |
US4325367A (en) | 1977-06-13 | 1982-04-20 | Robert Tapper | Iontophoretic treatment apparatus |
US4301794A (en) | 1978-10-18 | 1981-11-24 | Robert Tapper | Method for iontophoretic treatment |
US4838273A (en) | 1979-04-30 | 1989-06-13 | Baxter International Inc. | Medical electrode |
US4292968A (en) | 1979-11-26 | 1981-10-06 | Sybron Corporation | Electric supply for ion therapy |
SU931191A1 (en) | 1980-01-18 | 1982-05-30 | Предприятие П/Я А-3852 | Device for treating middle and internal ear |
SU1003853A1 (en) | 1980-03-17 | 1983-03-15 | Белорусский Научно-Исследовательский Институт Неврологии,Нейрохирургии И Физиотерапии | Device for electrophonoresis |
US4383529A (en) | 1980-11-03 | 1983-05-17 | Wescor, Inc. | Iontophoretic electrode device, method and gel insert |
US4416274A (en) | 1981-02-23 | 1983-11-22 | Motion Control, Inc. | Ion mobility limiting iontophoretic bioelectrode |
US4406658A (en) | 1981-03-06 | 1983-09-27 | Medtronic, Inc. | Iontophoretic device with reversible polarity |
US4820263A (en) | 1981-03-06 | 1989-04-11 | Medtronic, Inc. | Apparatus and method for iontophoretic drug delivery |
JPS5810066A (en) | 1981-07-10 | 1983-01-20 | 株式会社アドバンス | Plaster structure for ion tofuorese |
FR2513129A1 (en) | 1981-09-24 | 1983-03-25 | Moreau Lavaud Reine | Portable skin cosmetic treatment device - has current generator circuit breaker and holder for interchangeable electrodes incorporated into body |
US4393884A (en) | 1981-09-25 | 1983-07-19 | Jacobs Allen W | Demand inhaler for oral administration of tobacco, tobacco-like, or other substances |
US4429703A (en) | 1982-02-22 | 1984-02-07 | William Haber | Cigarette substitute |
US4510939A (en) | 1982-12-22 | 1985-04-16 | Biosonics, Inc. | Means for transferring electrical energy to and from living tissue |
US4639244A (en) | 1983-05-03 | 1987-01-27 | Nabil I. Rizk | Implantable electrophoretic pump for ionic drugs and associated methods |
US4708716A (en) | 1983-08-18 | 1987-11-24 | Drug Delivery Systems Inc. | Transdermal drug applicator |
US4919648A (en) | 1983-08-18 | 1990-04-24 | Drug Delivery Systems Inc. | High tack drug patch |
US5865786A (en) | 1983-08-18 | 1999-02-02 | Drug Delivery Systems, Inc. | Programmable control and mounting system for transdermal drug applicator |
US4808152A (en) | 1983-08-18 | 1989-02-28 | Drug Delivery Systems Inc. | System and method for controlling rate of electrokinetic delivery of a drug |
US5135479A (en) | 1983-08-18 | 1992-08-04 | Drug Delivery Systems, Inc. | Programmable control and mounting system for transdermal drug applicator |
CA1262564A (en) | 1983-09-01 | 1989-10-31 | Minoru Sasaki | Iontophoresis device |
US4813437A (en) | 1984-01-09 | 1989-03-21 | Ray J Philip | Nicotine dispensing device and method for the manufacture thereof |
US4655229A (en) | 1984-01-30 | 1987-04-07 | R. J. Reynolds Tobacco Company | Flavor delivery system |
US4665921A (en) | 1984-05-28 | 1987-05-19 | Teranishi Electric Works, Ltd. | High potential generating toothbrush |
US5135477A (en) | 1984-10-29 | 1992-08-04 | Medtronic, Inc. | Iontophoretic drug delivery |
US4747819A (en) | 1984-10-29 | 1988-05-31 | Medtronic, Inc. | Iontophoretic drug delivery |
SE8405479D0 (en) | 1984-11-01 | 1984-11-01 | Nilsson Sven Erik | WANT TO ADMINISTER VOCABULARY, PHYSIOLOGY, ACTIVE SUBJECTS AND DEVICE FOR THIS |
US4702732A (en) | 1984-12-24 | 1987-10-27 | Trustees Of Boston University | Electrodes, electrode assemblies, methods, and systems for tissue stimulation and transdermal delivery of pharmacologically active ligands |
US4800903A (en) | 1985-05-24 | 1989-01-31 | Ray Jon P | Nicotine dispenser with polymeric reservoir of nicotine |
JPS6222662A (en) | 1985-07-19 | 1987-01-30 | 林原 健 | Ion introducing electronic treatment device |
AT385664B (en) | 1985-07-31 | 1988-05-10 | Hepax Ltd | ELECTROMEDICAL THERAPY DEVICE |
US4756318A (en) | 1985-10-28 | 1988-07-12 | R. J. Reynolds Tobacco Company | Smoking article with tobacco jacket |
US4793366A (en) | 1985-11-12 | 1988-12-27 | Hill Ira D | Nicotine dispensing device and methods of making the same |
US4763660A (en) | 1985-12-10 | 1988-08-16 | Cherne Industries, Inc. | Flexible and disposable electrode belt device |
JPS62139672A (en) | 1985-12-14 | 1987-06-23 | 林原 健 | Remedy device for positive and negative iontophoresis |
US4767402A (en) | 1986-07-08 | 1988-08-30 | Massachusetts Institute Of Technology | Ultrasound enhancement of transdermal drug delivery |
US5961482A (en) | 1986-07-25 | 1999-10-05 | Rutgers, The State University Of New Jersey | Iontotherapeutic device and process and iontotherapeutic unit dose |
US5042975A (en) | 1986-07-25 | 1991-08-27 | Rutgers, The State University Of New Jersey | Iontotherapeutic device and process and iontotherapeutic unit dose |
US5250022A (en) | 1990-09-25 | 1993-10-05 | Rutgers, The State University Of New Jersey | Iontotherapeutic devices, reservoir electrode devices therefore, process and unit dose |
US4735217A (en) | 1986-08-21 | 1988-04-05 | The Procter & Gamble Company | Dosing device to provide vaporized medicament to the lungs as a fine aerosol |
JPS63135179A (en) | 1986-11-26 | 1988-06-07 | 立花 俊郎 | Subcataneous drug administration set |
US4771796A (en) | 1987-01-07 | 1988-09-20 | Fritz Myer | Electrically operated simulated cigarette |
US4931046A (en) | 1987-05-15 | 1990-06-05 | Newman Martin H | Iontophoresis drug delivery system |
US4787888A (en) | 1987-06-01 | 1988-11-29 | University Of Connecticut | Disposable piezoelectric polymer bandage for percutaneous delivery of drugs and method for such percutaneous delivery (a) |
US4865582A (en) | 1987-06-05 | 1989-09-12 | Drug Delivery Systems Inc. | Disposable transdermal drug applicators |
FR2619308B1 (en) | 1987-08-12 | 1993-12-17 | Oreal | MASSAGE APPARATUS |
JPS6456060A (en) | 1987-08-27 | 1989-03-02 | Hayashibara Takeshi | Low frequency medical treatment device |
US4942883A (en) | 1987-09-29 | 1990-07-24 | Newman Martin H | Drug delivery device |
JP2798459B2 (en) | 1988-01-21 | 1998-09-17 | マサチユセツツ・インスチチユート・オブ・テクノロジー | Diagnostic device using electroporation and device for moving molecules into tissue |
US5362307A (en) | 1989-01-24 | 1994-11-08 | The Regents Of The University Of California | Method for the iontophoretic non-invasive-determination of the in vivo concentration level of an inorganic or organic substance |
JP2907342B2 (en) | 1988-01-29 | 1999-06-21 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | Ion infiltration non-invasive sampling or delivery device |
US4957480A (en) | 1988-02-02 | 1990-09-18 | Universal Health Products, Inc. | Method of facial toning |
IL86076A (en) | 1988-04-14 | 1992-12-01 | Inventor S Funding Corp Ltd | Transdermal drug delivery device |
US4997418A (en) | 1988-04-21 | 1991-03-05 | C. P. Chambers | Epidermal iontophoresis device |
US5162042A (en) | 1988-07-05 | 1992-11-10 | Alza Corporation | Electrotransport transdermal system |
IL87004A (en) * | 1988-07-06 | 1992-08-18 | Technion Res & Dev Foundation | Method and apparatus for bioaffinity separation |
US4922901A (en) | 1988-09-08 | 1990-05-08 | R. J. Reynolds Tobacco Company | Drug delivery articles utilizing electrical energy |
CA2001444C (en) | 1988-10-28 | 2000-07-25 | Darrel F. Untereker | Iontophoresis electrode |
US5501705A (en) | 1988-10-31 | 1996-03-26 | Fakhri; Omar | Method for the treatment of psoriasis with electric current |
US5006108A (en) | 1988-11-16 | 1991-04-09 | Noven Pharmaceuticals, Inc. | Apparatus for iontophoretic drug delivery |
US4917119A (en) | 1988-11-30 | 1990-04-17 | R. J. Reynolds Tobacco Company | Drug delivery article |
US5135478A (en) | 1989-05-10 | 1992-08-04 | Drug Delivery Systems Inc. | Multi-signal electrical transdermal drug applicator |
US4979938A (en) | 1989-05-11 | 1990-12-25 | Iomed, Inc. | Method of iontophoretically treating acne, furuncles and like skin disorders |
US5374241A (en) | 1989-07-21 | 1994-12-20 | Iomed, Inc. | Electrodes for iontophoresis |
US4950229A (en) | 1989-09-25 | 1990-08-21 | Becton, Dickinson And Company | Apparatus for an electrode used for iontophoresis |
US5060671A (en) | 1989-12-01 | 1991-10-29 | Philip Morris Incorporated | Flavor generating article |
US5047007A (en) | 1989-12-22 | 1991-09-10 | Medtronic, Inc. | Method and apparatus for pulsed iontophoretic drug delivery |
US5115805A (en) | 1990-02-23 | 1992-05-26 | Cygnus Therapeutic Systems | Ultrasound-enhanced delivery of materials into and through the skin |
JP2816886B2 (en) | 1990-03-05 | 1998-10-27 | 興和株式会社 | Bioelectric device |
AU647103B2 (en) | 1990-03-30 | 1994-03-17 | Alza Corporation | Iontophoretic delivery device |
US6004309A (en) | 1990-03-30 | 1999-12-21 | Alza Corporation | Method and apparatus for controlled environment electrotransport |
US5133352A (en) | 1990-04-12 | 1992-07-28 | Kent, Lathrop And Johnston | Method for treating herpes simplex |
US5167242A (en) | 1990-06-08 | 1992-12-01 | Kabi Pharmacia Aktiebolaq | Nicotine-impermeable container and method of fabricating the same |
US5147291A (en) | 1990-06-11 | 1992-09-15 | Cukier A David | Sound transmission apparatus for uniformly administering chemical composition through the skin |
US5037381A (en) | 1990-07-27 | 1991-08-06 | Bock C Randolph | Electrically assisted transdermal transport device and method for renewing the device |
US5362308A (en) | 1990-09-25 | 1994-11-08 | Rutgers, The State University Of New Jersey | Disposable dosage unit for iontophoresis-facilitated transdermal delivery, related devices and processes |
DE4114677A1 (en) | 1990-10-10 | 1992-02-27 | Mario Bergner | APPLICATION ARRANGEMENT OF DIFFERENT ELECTRICALLY CONNECTED METALS ON THE HUMAN BODY TO A BIOELECTRIC SYSTEM IN THE MEANING OF THE ELECTROCHEMICAL VOLTAGE RANGE WITH VOLTAGE INCREASING WITH POSSIBLE USE OF COMMERCIAL ECG FLASHER ELEMENTS |
US6238381B1 (en) * | 1990-11-01 | 2001-05-29 | Robert Tapper | Iontophoretic treatment system |
US5254081A (en) | 1991-02-01 | 1993-10-19 | Empi, Inc. | Multiple site drug iontophoresis electronic device and method |
NL9100662A (en) | 1991-04-17 | 1992-11-16 | Optische Ind De Oude Delft Nv | DEVICE FOR PERFORMING AN ITHOPHORESIS TREATMENT ON A PATIENT. |
DE4120517A1 (en) | 1991-06-18 | 1992-12-24 | Kleditsch Bernhard Dr Med Dent | DC GENERATOR FOR THE TREATMENT OF THE INITIAL STAGE HERPES LABIALIS AND OTHER INITIAL INFLAMMATION OF THE HAUTAREAL |
GB2257632B (en) | 1991-07-17 | 1995-03-22 | Innovative Medical Devices | Skin treatment device |
US5203768A (en) | 1991-07-24 | 1993-04-20 | Alza Corporation | Transdermal delivery device |
US5464387A (en) | 1991-07-24 | 1995-11-07 | Alza Corporation | Transdermal delivery device |
US5169384A (en) | 1991-08-16 | 1992-12-08 | Bosniak Stephen L | Apparatus for facilitating post-traumatic, post-surgical, and/or post-inflammatory healing of tissue |
US5171215A (en) | 1991-08-22 | 1992-12-15 | Flanagan Dennis F | Endermic method and apparatus |
EP0615461B1 (en) | 1991-12-03 | 1996-09-25 | Alza Corporation | Iontophoretic delivery device and power supply therefor |
CA2087087C (en) | 1992-01-22 | 2000-07-18 | Burton H. Sage, Jr. | Molecules for iontophoretic delivery |
US5360440A (en) | 1992-03-09 | 1994-11-01 | Boston Scientific Corporation | In situ apparatus for generating an electrical current in a biological environment |
US5589563A (en) | 1992-04-24 | 1996-12-31 | The Polymer Technology Group | Surface-modifying endgroups for biomedical polymers |
DE69407061T2 (en) | 1992-06-02 | 1998-06-04 | Alza Corp | DISPENSING DEVICE FOR THE ELECTRICAL TRANSMISSION OF MEDICINAL PRODUCTS |
US5312326A (en) | 1992-06-02 | 1994-05-17 | Alza Corporation | Iontophoretic drug delivery apparatus |
US5607691A (en) | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
US5331979A (en) | 1992-07-27 | 1994-07-26 | Henley Julian L | Iontophoretic cigarette substitute |
US5688233A (en) | 1992-08-17 | 1997-11-18 | Genetronics, Inc. | Electronincorporation enhanced transdermal delivery of molecules |
US5421816A (en) | 1992-10-14 | 1995-06-06 | Endodermic Medical Technologies Company | Ultrasonic transdermal drug delivery system |
US5322520A (en) | 1992-11-12 | 1994-06-21 | Implemed, Inc. | Iontophoretic structure for medical devices |
US5298017A (en) | 1992-12-29 | 1994-03-29 | Alza Corporation | Layered electrotransport drug delivery system |
ATE190233T1 (en) | 1992-12-31 | 2000-03-15 | Alza Corp | ELECTRIC TRANSPORT DEVICE |
US5443441A (en) | 1993-03-05 | 1995-08-22 | De Claviere; Anne Marie | Apparatus and method for transdermal delivery of cosmetic compositions |
US6004547A (en) | 1997-09-29 | 1999-12-21 | Focal, Inc. | Apparatus and method for local application of polymeric material to tissue |
US5667487A (en) | 1993-04-07 | 1997-09-16 | Henley; Julian L. | Ionosonic drug delivery apparatus |
US5458569A (en) | 1993-06-08 | 1995-10-17 | Becton Dickinson And Company | Wearable iontophoresis system |
FR2709670B1 (en) | 1993-09-10 | 1995-10-20 | Asulab Sa | Device in three modules for transdermal administration of drugs by electrophoresis or iontophoresis. |
US5415629A (en) * | 1993-09-15 | 1995-05-16 | Henley; Julian L. | Programmable apparatus for the transdermal delivery of drugs and method |
JPH09503136A (en) | 1993-09-30 | 1997-03-31 | ベクトン・ディッキンソン・アンド・カンパニー | Iontophoresis drug delivery system and method |
US5540669A (en) | 1993-09-30 | 1996-07-30 | Becton, Dickinson And Company | Iontophoretic drug delivery system and method for using same |
US5458140A (en) | 1993-11-15 | 1995-10-17 | Non-Invasive Monitoring Company (Nimco) | Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers |
US5441936A (en) | 1993-12-07 | 1995-08-15 | Houghten Pharmaceuticals, Inc. | Antiviral peptides |
US5554361A (en) | 1994-01-21 | 1996-09-10 | Dixon; Gary W. | Processed product for skin and hair treatment |
WO1995035132A1 (en) | 1994-06-17 | 1995-12-28 | Hisamitsu Pharmaceutical Co., Inc. | Electrode for iontophoresis and device using the same |
US6048545A (en) | 1994-06-24 | 2000-04-11 | Biozone Laboratories, Inc. | Liposomal delivery by iontophoresis |
WO1996002232A1 (en) | 1994-07-13 | 1996-02-01 | Alza Corporation | Composition and method for enhancing transdermal electrotransport agent delivery |
US5795321A (en) | 1994-09-30 | 1998-08-18 | Becton Dickinson And Company | Iontophoretic drug delivery system, including removable controller |
US5514167A (en) | 1994-10-24 | 1996-05-07 | Mgb Technologies Corporation | Hand holdable human skin treatment apparatus |
US5551953A (en) | 1994-10-31 | 1996-09-03 | Alza Corporation | Electrotransport system with remote telemetry link |
US5736580A (en) | 1994-11-14 | 1998-04-07 | Alza Croporation | Composition, device, and method for electrotransport agent delivery |
FR2726770B1 (en) | 1994-11-16 | 1997-01-31 | Lhd Lab Hygiene Dietetique | TRANSDERMAL DRUG DELIVERY DEVICE FOR THE TREATMENT OF MALE ERECTILE IMPOTENCE |
JP3170172B2 (en) | 1995-03-30 | 2001-05-28 | ティーディーケイ株式会社 | Chip component supply device and chip component supply case used for the device |
US5697896A (en) | 1994-12-08 | 1997-12-16 | Alza Corporation | Electrotransport delivery device |
DE69530290T2 (en) | 1995-01-27 | 2004-01-29 | Alessandro Aloisi | DEVICE FOR IONTOPHORETIC PHYSIOTHERAPY WITH FROZEN MEDICAL CRYSTALS |
EP0819016A1 (en) | 1995-04-07 | 1998-01-21 | Novartis AG | Iontophoretic transdermal system for the administration of at least two substances |
US5882676A (en) | 1995-05-26 | 1999-03-16 | Alza Corporation | Skin permeation enhancer compositions using acyl lactylates |
US5983130A (en) | 1995-06-07 | 1999-11-09 | Alza Corporation | Electrotransport agent delivery method and apparatus |
US6041252A (en) | 1995-06-07 | 2000-03-21 | Ichor Medical Systems Inc. | Drug delivery system and method |
US5788666A (en) | 1995-06-15 | 1998-08-04 | Empi, Inc. | Iontophoresis electrode |
US6041253A (en) | 1995-12-18 | 2000-03-21 | Massachusetts Institute Of Technology | Effect of electric field and ultrasound for transdermal drug delivery |
US5674546A (en) * | 1995-08-10 | 1997-10-07 | Nabisco Technology Company | Package for storing and cooking an omelet |
WO1997011742A1 (en) | 1995-09-28 | 1997-04-03 | Becton Dickinson And Company | Iontophoretic drug delivery system, including disposable patch |
WO1997014473A1 (en) | 1995-10-18 | 1997-04-24 | Novartis Ag | Thermopile powered transdermal drug delivery device |
US5607461A (en) | 1995-10-20 | 1997-03-04 | Nexmed, Inc. | Apparatus and method for delivering electrical stimulus to tissue |
US5618275A (en) | 1995-10-27 | 1997-04-08 | Sonex International Corporation | Ultrasonic method and apparatus for cosmetic and dermatological applications |
US5755750A (en) | 1995-11-13 | 1998-05-26 | University Of Florida | Method and apparatus for selectively inhibiting activity in nerve fibers |
US5678273A (en) * | 1996-03-20 | 1997-10-21 | Porcelli; V. Lorenzo | Disposable oral hygiene applicator |
FR2747313B1 (en) | 1996-04-16 | 1998-06-05 | Lhd Lab Hygiene Dietetique | TRANSDERMAL MEDICINE DELIVERY DEVICE BY IONOPHORESIS |
US6385487B1 (en) * | 1996-05-08 | 2002-05-07 | Biophoretic Therapeutic Systems, Llc | Methods for electrokinetic delivery of medicaments |
US5676648A (en) * | 1996-05-08 | 1997-10-14 | The Aps Organization, Llp | Iontophoretic drug delivery apparatus and method for use |
EP0920345A4 (en) | 1996-06-19 | 2006-05-10 | Vyteris Inc | Iontophoretic delivery of cell adhesion inhibitors |
US5797867A (en) | 1996-09-27 | 1998-08-25 | Becton Dickinson And Company | Iontophoretic drug delivery system, including method for activating same for attachment to patient |
US5713846A (en) | 1996-09-27 | 1998-02-03 | Becton Dickinson And Company | Iontophoretic drug delivery system, including method for activating same for attachment to patient |
ATE274972T1 (en) * | 1996-12-26 | 2004-09-15 | Elan Internat Services Ltd | ELECTRODE UNIT FOR A DEVICE FOR ADMINISTRATION OF MEDICATION |
US6018679A (en) | 1997-01-29 | 2000-01-25 | Novartis Finance Corp. | Iontophoretic transdermal delivery and control of adverse side-effects |
US5794774A (en) * | 1997-05-12 | 1998-08-18 | Porcelli; V. Lorenzo | Disposable oral hygiene applicator |
US5911319A (en) * | 1997-05-12 | 1999-06-15 | John J. Stoltzfus | Blister package for oral hygiene applicators |
US5904712A (en) | 1997-06-12 | 1999-05-18 | Axelgaard Manufacturing Co., Ltd. | Current-controlling electrode |
US5846217A (en) | 1997-07-29 | 1998-12-08 | Iomed, Inc. | Iontophoretic bioelectrode and method of using same |
US5899876A (en) | 1997-08-27 | 1999-05-04 | Becton, Dickinson And Company | Multiple site drug delivery system |
TW368420B (en) | 1997-11-04 | 1999-09-01 | Genetronics Inc | Apparatus and method for transdermal molecular delivery by applying sufficient amplitude of electric field to induce migration of molecules through pores in the stratum corneum |
US5968005A (en) | 1998-01-07 | 1999-10-19 | Tu; Hosheng | Devices and means for treating canker sores |
IL122875A0 (en) * | 1998-01-08 | 1998-08-16 | S L P Ltd | An integrated sleep apnea screening system |
US6023639A (en) | 1998-05-01 | 2000-02-08 | Hakky; Said | Non-invasive bodily fluid withdrawal and monitoring system |
JP4297401B2 (en) * | 1998-09-15 | 2009-07-15 | トランスポート・ファーマシューティカルズ・インコーポレイテッド | Drug delivery electrode by ion osmosis therapy |
US6148231A (en) | 1998-09-15 | 2000-11-14 | Biophoretic Therapeutic Systems, Llc | Iontophoretic drug delivery electrodes and method |
US6101411A (en) | 1998-09-24 | 2000-08-08 | Newsome; David A. | Dilation enhancer |
US5931859A (en) | 1998-09-30 | 1999-08-03 | Burke; Robert E. | Facial toning system |
US6148232A (en) | 1998-11-09 | 2000-11-14 | Elecsys Ltd. | Transdermal drug delivery and analyte extraction |
US6553253B1 (en) * | 1999-03-12 | 2003-04-22 | Biophoretic Therapeutic Systems, Llc | Method and system for electrokinetic delivery of a substance |
US6477410B1 (en) | 2000-05-31 | 2002-11-05 | Biophoretic Therapeutic Systems, Llc | Electrokinetic delivery of medicaments |
-
2000
- 2000-05-31 US US09/584,138 patent/US6477410B1/en not_active Expired - Fee Related
-
2001
- 2001-05-21 EP EP01941502A patent/EP1294438A4/en not_active Withdrawn
- 2001-05-21 AU AU2001274851A patent/AU2001274851B2/en not_active Ceased
- 2001-05-21 BR BR0111288-0A patent/BR0111288A/en not_active Application Discontinuation
- 2001-05-21 AU AU7485101A patent/AU7485101A/en active Pending
- 2001-05-21 JP JP2001587863A patent/JP4199457B2/en not_active Expired - Lifetime
- 2001-05-21 CA CA002413806A patent/CA2413806C/en not_active Expired - Fee Related
- 2001-05-21 CN CNB018103790A patent/CN1287877C/en not_active Expired - Fee Related
- 2001-05-21 WO PCT/US2001/016069 patent/WO2001091853A1/en active IP Right Grant
- 2001-05-21 MX MXPA02011842A patent/MXPA02011842A/en active IP Right Grant
- 2001-05-21 EP EP10012024A patent/EP2277584A1/en not_active Withdrawn
- 2001-05-21 RU RU2002135648/14A patent/RU2268075C2/en not_active IP Right Cessation
-
2002
- 2002-09-18 US US10/245,337 patent/US6735470B2/en not_active Expired - Lifetime
-
2003
- 2003-09-16 HK HK03106645.3A patent/HK1054338A1/en unknown
-
2004
- 2004-03-24 US US10/807,295 patent/US7069073B2/en not_active Expired - Fee Related
-
2005
- 2005-04-13 US US11/104,568 patent/US20050182351A1/en not_active Abandoned
- 2005-10-24 AU AU2005225129A patent/AU2005225129B2/en not_active Ceased
- 2005-11-03 US US11/265,383 patent/US20060052739A1/en not_active Abandoned
-
2007
- 2007-10-24 AU AU2007231635A patent/AU2007231635A1/en not_active Abandoned
-
2010
- 2010-05-17 AU AU2010201975A patent/AU2010201975A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5160316A (en) | 1990-09-10 | 1992-11-03 | Henley Julian L | Iontophoretic drug delivery apparatus |
US5310404A (en) * | 1992-06-01 | 1994-05-10 | Alza Corporation | Iontophoretic delivery device and method of hydrating same |
US5562607A (en) * | 1995-01-18 | 1996-10-08 | Alza Corporation | Electrotransport device having reusable controller power saver |
US5908401A (en) * | 1996-05-08 | 1999-06-01 | The Aps Organization, Llp | Method for iontophoretic delivery of antiviral agents |
Non-Patent Citations (1)
Title |
---|
See also references of EP1294438A4 |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005225129B2 (en) * | 2000-05-31 | 2007-07-26 | Biophoretic Therapeutic Systems, Llc | Electrokinetic delivery device |
EP1418919A2 (en) * | 2001-07-20 | 2004-05-19 | Iomed, Inc. | The use of 5 fluorourcil, delivered by inotophoresis as an inhibitor of cell proliferation in the eye, bulbar and palpebral conjunctiva, eyelid, peri-orbital soft tissues and skin |
EP1418919A4 (en) * | 2001-07-20 | 2007-06-13 | Iomed Inc | The use of 5 fluorourcil, delivered by inotophoresis as an inhibitor of cell proliferation in the eye, bulbar and palpebral conjunctiva, eyelid, peri-orbital soft tissues and skin |
AU2003234691B2 (en) * | 2002-04-08 | 2007-08-02 | Biophoretic Therapeutic Systems, Llc | Finger-mounted electrokinetic delivery system |
AU2003234691B8 (en) * | 2002-04-08 | 2003-10-27 | Biophoretic Therapeutic Systems, Llc | Finger-mounted electrokinetic delivery system |
AU2007203591B2 (en) * | 2002-04-08 | 2010-07-29 | Biophoretic Therapeutic Systems, Llc | Finger-mounted electrokinetic delivery system for self-administration of medicaments |
EP1496987A1 (en) * | 2002-04-08 | 2005-01-19 | Biophoretic Therapeutic Systems, LLC | Finger-mounted electrokinetic delivery system |
EP1496987A4 (en) * | 2002-04-08 | 2005-08-24 | Biophoretic Therapeutic System | Finger-mounted electrokinetic delivery system |
FR2844719A1 (en) * | 2002-09-24 | 2004-03-26 | Francois Duret | Electro-chemical whitening device for dental or medical use comprises electric, electrophoretic or electromagnetic field generator with associated whitening agent application and activation means |
WO2004028626A1 (en) * | 2002-09-24 | 2004-04-08 | Duret Francois | Bleaching device employing electro-optical and chemical means, which is intended, in particular, for use in the medical and dental field |
WO2004105864A1 (en) * | 2003-06-03 | 2004-12-09 | Eyegate Pharma S.A. | Ocular device for current controlled variable delivery of active principles |
FR2855761A1 (en) * | 2003-06-03 | 2004-12-10 | Optis France Sa | EYE DEVICE FOR VARIABLE DELIVERY OF ACTIVE PRINCIPLES BY IONTOPHORESIS |
EP2474281B1 (en) * | 2003-12-24 | 2019-03-27 | The Regents of The University of California | Tissue ablation with irreversible electroporation |
US10518073B2 (en) | 2006-06-15 | 2019-12-31 | Polypharma Pty Ltd | Delivery system and process |
WO2014164842A1 (en) * | 2013-03-11 | 2014-10-09 | Birchwood Laboratories, Inc. | Sweat analyte testing components and methods |
EP2996756B1 (en) * | 2013-05-15 | 2020-12-16 | Solvamed GmbH | Skin applicator for applying highly volatile substances |
US11806163B2 (en) | 2018-10-09 | 2023-11-07 | Inter.mix, Inc. | Hydration testing article |
Also Published As
Publication number | Publication date |
---|---|
US6735470B2 (en) | 2004-05-11 |
CN1437493A (en) | 2003-08-20 |
CA2413806A1 (en) | 2001-12-06 |
CA2413806C (en) | 2006-09-19 |
HK1054338A1 (en) | 2003-11-28 |
JP4199457B2 (en) | 2008-12-17 |
MXPA02011842A (en) | 2004-03-02 |
AU2005225129A1 (en) | 2005-11-10 |
AU7485101A (en) | 2001-12-11 |
AU2007231635A1 (en) | 2007-11-15 |
CN1287877C (en) | 2006-12-06 |
US7069073B2 (en) | 2006-06-27 |
EP1294438A1 (en) | 2003-03-26 |
RU2002135648A (en) | 2004-03-27 |
US6477410B1 (en) | 2002-11-05 |
AU2005225129B2 (en) | 2007-07-26 |
EP2277584A1 (en) | 2011-01-26 |
US20030018295A1 (en) | 2003-01-23 |
JP2003534108A (en) | 2003-11-18 |
US20040176737A1 (en) | 2004-09-09 |
AU2001274851B2 (en) | 2005-08-04 |
US20050182351A1 (en) | 2005-08-18 |
AU2010201975A1 (en) | 2010-06-03 |
EP1294438A4 (en) | 2005-12-07 |
RU2268075C2 (en) | 2006-01-20 |
US20060052739A1 (en) | 2006-03-09 |
BR0111288A (en) | 2003-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6477410B1 (en) | Electrokinetic delivery of medicaments | |
US8328788B2 (en) | Methods and systems for electrokinetic delivery of a substance | |
AU2001274851A2 (en) | Electrokinetic delivery device | |
AU2001274851A1 (en) | Electrokinetic delivery device | |
US5167616A (en) | Iontophoretic delivery method | |
KR200403033Y1 (en) | Portable skin care device for beauty pack | |
US5298017A (en) | Layered electrotransport drug delivery system | |
US5403275A (en) | Method for reducing sensation in iontophoretic drug delivery | |
JP3821837B2 (en) | Electrically driven iontophoretic agent administration device | |
CA2038968C (en) | Iontophoretic delivery device | |
US5158537A (en) | Iontophoretic delivery device and method of hydrating same | |
US5162043A (en) | Iontophoretic delivery device | |
CA2090313A1 (en) | Iontophoretic delivery device and method of hydrating same | |
IE83316B1 (en) | Device for reducing sensation during iontophoretic drug delivery | |
AU2002363106A1 (en) | Device and method for controlled delivery of active substance into the skin | |
WO2003035167A2 (en) | Device and method for controlled delivery of active substance into the skin | |
US20080319371A1 (en) | Method and system for treating of onychomycosis with an applicator having a gel medicament layer | |
JP4297401B2 (en) | Drug delivery electrode by ion osmosis therapy | |
CA2042994C (en) | Iontophoretic delivery device | |
KR20230091270A (en) | A collagen-producing portable beauty device that maximizes the anti-aging effect that stimulates skin cells using microcurrents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001274851 Country of ref document: AU Ref document number: IN/PCT/2002/01127/DE Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2001 587863 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/011842 Country of ref document: MX Ref document number: 018103790 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2413806 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001941502 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001941502 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001274851 Country of ref document: AU |